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 Bacteria have evolved several mechanisms to promote their survival, which 
sometimes come at the cost of human health.  They use toxins known as virulence factors 
to cause the symptoms associated with infections.  They also form communities called 
biofilm, which allow them to thrive and resist attacks by the host’s immune system. 
Conventional antibiotics fail to penetrate the biofilm matrix.  The expression of virulence 
factors and formation of biofilm are both regulated by a phenomenon known as quorum 
sensing.  Quorum sensing is a form of cell-to-cell communication, which allows bacteria 
to coordinate gene expression via the secretion of signaling molecules, known as 
autoinducers, and the subsequent detection of these molecules. The ultimate goal of this 
dissertation was to identify new small molecules that would be used to disrupt quorum 
sensing in bacteria.  AI-2, which is a universal quorum sensing autoinducer, found in 
over 60 bacterial species, was targeted.  In this study a new facile synthesis of AI-2 was 
achieved and this new methodology was adapted to the synthesis of a library of analogs.  
 
 
These analogs were screened for their ability to modulate AI-2 mediated quorum sensing 
in Vibrio harveyi, Escherichia coli, Salmonella typhimurium and Pseudomonas 
aeruginosa.  It was found that AI-2 analogs were able to cause synergistic agonism of 
bioluminescence in V. harveyi.  Furthermore, several analogs were able to repress 
quorum sensing in E. coli yet very few analogs were active in the homologous quorum 
sensing system of S. typhimurium. These analogs were processed by the AI-2 processing 
enzymes in E. coli.  Finally some AI-2 analogs were found to inhibit quorum sensing in 
P. aeruginosa in pure culture as well as in mixed cultures.  These findings will provide 
the framework for the development of new small molecules which are able to modulate 
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1.1 New approaches to anti-infective chemotherapy 
Over the last two decades the treatment of bacterial infections has become non-
trivial due to the rapid development of resistance and the emergence of multi-drug 
resistant organisms.1 By 2003, 50% of all hospital infections were caused by methicillin-
resistant Staphylococcus aureus (MRSA).1 In 2007, 70% of all hospital-acquired 
infections were resistant to at least one or more antibiotic.2 Today, community-acquired 
MRSA as well as vancomycin-resistant S. aureus (VRSA) and vancomycin-resistant 
Enterococci (VRE) are less susceptible to newer drugs such as daptomycin and 
linozelid.1 Since antibiotics are designed to be lethal to bacteria (bactericidal)  or inhibit 
their growth (bacteriostatic), evolutionary pressure is placed on the organism to develop 
mechanisms of resistance.2-3 Such mechanisms include alteration of the drug target, 
degradation of the drug molecule or rapid expulsion of the drug out of the cell.2-3 
Progress has been made in developing anti-infective agents which have novel targets 
including riboswitches, fatty acid synthesis, and programmed cell death.3 However, since 
these processes are vital for the survival of bacteria it is inevitable that resistance will 
soon develop.3  
Bacteria communicate through the secretion and detection of small molecules in a 
process known as quorum sensing.3a, 4 Once a critical population is reached bacteria 
coordinate the expressions of genes required for processes such as virulence, biofilm 
formation, and bioluminescence.4 Virulence factor expression is responsible for the 




persistence of infections as well as difficulties encountered when trying to kill bacteria 
with antibiotics.2-3  
Virulence is accomplished through the secretion of factors such as toxins and 
proteases, which directly affect host cell function.2  Bacteria only express these factors 
when the population is large enough to be effective.2 It has been shown that quorum 
sensing regulates the expression of these virulence genes.5 As bacteriocidal drugs put 
enormous pressure on bacteria to develop resistance, it has been suggested that strategies 
such as quorum sensing inhibition, which attenuate bacterial virulence but do not kill 
bacteria, might lead to less resistance development.2-3 
Biofilm is a community of bacteria encapsulated in a polysaccharide matrix; this 
matrix can form on surfaces such as living tissues or medical devices.6 Once incorporated 
in a biofilm matrix, bacteria are resistant to traditional antibiotics and are rarely cleared 
by the host immune system.6-7 Also the biofilm environment increases the probability of 
antibiotic-resistant plasmid being transferred between bacteria.6b Biofilm is involved in 
over 60% of bacterial infections.3a, 6a However there is currently no anti-biofilm drug in 
clinical use.3a, 6a Since quorum sensing has been shown to be involved in biofilm 
formation, anti-quorum sensing agents may provide a mean to clear biofilm infections. 
 Although not proven clinically there are several reasons why attenuating virulence 
and biofilm formation by interfering with quorum sensing is less likely to cause 
resistance.  Firstly mutation of quorum sensing proteins in order to overcome the action 
of anti-quorum sensing agents would cause the organism to be unresponsive to the 
natural signaling molecules.  Therefore it would not be able to detect when a threshold 




dependent behavior, mutating a quorum sensing protein will cause the organism to be 
“out of sync” with the other bacteria.  Although the mutated organism will be able to 
overcome the action of the anti-quorum sensing agents its neighbors will not.  Thus the 
mutated organism will turn quorum sensing “on” independently.  Ultimately its efforts to 
conduct processes such as biofilm formation and virulence expression will be inadequate 
and the host immune system can easily clear these lone mutants.  Finally there is no 
growth advantage in developing anti-quorum sensing-resistance like that of antibiotic-
resistance where mutation allows the organism to thrive and replicate.  If a mutation of 
quorum sensing proteins does occur, the forementioned discussions suggest that this 
mutant may be at a growth disadvantage.  Therefore targeting quorum sensing as a new 
















1.2 Quorum sensing of gram-negative and gram-positive organism 
 
Figure 1.1: Autoinducers used in quorum sensing3a 
 
Quorum sensing involves the release of signaling molecules called autoinducers. 
Generally gram-negative bacteria use acylhomoserine lactones (AHLs) with varying 
acyl-chain lengths (3-7; Figure 1.1) whereas gram-positive species use oligopeptides, 
which may be post-translationally modified (1-2; Figure 1.1) for intra-species 
communication.4a,8 In gram-negative bacteria, such as Vibrio fischeri and Pseudomonas 
aeruginosa, AHLs are produced by a LuxI-type synthase proteins and detected by a 
LuxR-type cytoplasmic receptor proteins, which bind to DNA in order to activate or 






Figure 1.2: a) crystal structure of TraR bound to DNA b) AHL in binding site of TraR 
 
The bioluminescent marine bacterium, V. fischeri, uses 3-oxo-hexanoyl-
homoserine lactone (3OC6-HSL; 7) and N-octanoyl-homoserine lactone (C8-HSL; 5) for 
intraspecies communication.3a, 10 The opportunistic organism P. aeruginosa uses two 
AHLS: N-butyryl-homoserine lactone (C4-HSL; 3) and N-3-oxo-dodecanoyl-homoserine 
lactone (3OC12-HSL; 6) in a dual quorum sensing system.3a, 4a, 10 3OC12-HSL is 
produced by LasI and detected by LasR while C4-HSL is produced by RhlI and is 
detected by RhlR.3a, 4a The las system controls the rhl system as well as several virulence 
factors.3a, 4a P. aeruginosa also secrete other signaling molecules including 2-heptyl-3-
hydroxyl-4-quinolone (Pseudomonas quinolone signal; (PQS), 8) and piperazines (9).3a, 
4a Other Vibrios such as V. cholerae and V. harveyi use parallel quorum sensing signals.11  
In V. cholorae, the signaling molecules are S-3 hydroxydodecan-4-one (CAI-1; 10) and 
AI-2 (11-13).3a, 4a, 11 CAI-1 and AI-2 are synthesized by CqsA and LuxS, respectively and 
then detected by the membrane bound proteins CqsS and LuxPQ, respectively. 3a, 4a, 11 In 





by LuxN. 3a, 11 Enterohaemorrhagic E. coli (EHEC) use an unidentified compound known 
as AI-3 for signaling along with the hormones epinephrine and norepinephrine.4b, c, 12 AI-
3 binds the membrane bound protein QseC, which initiates a phospho-relay and triggers 
the expression of genes responsible for attaching and effacing lesions.4b, c, 12 The quorum 
sensing systems of the bacteria described above are well understood and attempts to 
target these organisms for anti-infective chemotherapy have been pursued.10, 13 
 
1.3 Quorum sensing inhibitors 
Researchers have found that in nature bacteria target the quorum sensing 
communication system of other organisms in competition for resources. This is 
accomplished through quorum quenching enzymes (i.e. lactonases and acylases)14 which 
degrade the signaling molecules before they are able to initiate quorum sensing.  
Unfortunately anti-quorum sensing chemotherapies are unlikely to use proteins due to 
their potential to cause an immune system response.  Instead small molecules are better 
candidates for anti-quorum sensing studies. 
 





Nature provides several examples of small molecules that interfere with quorum 
sensing (Figure 1.3).  For example, patulin (14) and penicillic acid (15), present in the 
broth of Penicillium, were able to down regulate gene expression in P. aeruginosa.15 A 
component of garlic extract, GC-7 (16), was able to inhibit V. fischeri signaling 
systems.3a The food additive cinnamaldehyde (17) was found to be a potent inhibitor of 
AI-2 mediated quorum sensing in several Vibrios.16 Derivatives of cinnamaldehyde were 
also screened however only 4-NO2-cinnamaldehyde was more active than the parent 
compound, but it suffered from toxicity.16 The mechanism of inhibition of 
cinnamaldehyde was found to be due to binding to the master regulator LuxR found in V. 
harveyi. 16  
The most well known natural inhibitors of quorum sensing are the brominated 
furanones, which are produced by red algae.17 Brominated furanones have been found to 
inhibit biofilm formation in S. typhimurium and P. aeruginosa.18 Synthetic derivatives of 
these brominated furanones (18 and 19) have demonstrated inhibition of P. aeruginosa 
biofilm formation in vitro as well as in vivo on mice models.17-18 Both natural (20) and 
synthetic brominated furanones (21) are able to reduce biofilm formation in S. 
typhimurium.18b Though the synthetic analog (21) was slightly less active, it had a lower 
toxicity.18b Initial studies found that brominated furanones inhibit quorum sensing by 
targeting LuxR.17, 19 However, a recent study found that these compounds can covalently 
modify LuxS.20 These examples confirm that small molecules can indeed effect quorum 




Taking lead from nature, synthetic molecules have been developed to block the 
synthesis, binding or other downstream signaling events caused by autoinducers using 
structural analogs or compounds identified by high throughput screening.13 
  
 
Scheme 1.1: Biosynthesis of AHLs3a (ACP= acyl-carrier proteins) 
 
In the biosynthesis of AHLs, LuxI-type enzymes catalyze the reaction of the fatty 
acid portion of acyl carrier proteins with S-adenosylmethionine (SAM (22) to form AHLs 
and methylthioadenosine (MTA, 23; see Scheme 1.1).3a, 10, 21 The nucleosidase, Pfs then 
converts MTA into methylthioribose (MTR; 24), which forms methionine (25).3a, 10, 21  
 
 






Recent work by Schramm involved the synthesis of a library of transition state 
analogs of MTA as inhibitors of the methylthioadenosine nuclease (MTAN, (Pfs); See 
Figure 1.4).22 Originally, early stage transition state analogs were designed and p-
chlorophenylthio-ImmA (pClPhT-ImmA; 26) was found to be the tightest binder of Pfs.22 
A newer generation of analogs were designed to mimic late stage transition states; in this 
series p-chlorophenylthio-DADMe-ImmA (27) was  also the best binder.22 Additionally 
But-DADMe-ImmA (28) was able to effect biofilm formation in V. cholerae and E. coli 
O157:H7.23 Although this approach has given promising results, MTANs are vital for 
polyamine synthesis, methyl transfer and methionine synthesis in human cells as well as 
in bacteria. 23 Therefore these molecules are likely to be toxic due to their potential to 
interfere with important metabolic process in human cells. 
 




Structural analogs of AHLs are the most widely explored set of small molecule 
modulators of quorum sensing (Figure 1.5).10 As previously described, AHLs of different 
chain lengths are used for signaling between specific species of bacteria.4a, 10 Early 
studies showed that alteration of the structure of the AHL often resulted in reduced 
agonism or in some cases antagonism via competition with the natural ligand for binding 
to  LuxR-type proteins.24 Initial results showed that C9-AHL (29), which is only one 
carbon longer than the natural AHL, was a potent inhibitor of LuxR mediated 
bioluminescence in V. fischeri.24 Following the introduction of a new synthetic route, 
over 90 analogs with non-native AHLs have been synthesized and evaluated in A. 
tumefaciens, P. aeruginosa and V. fischeri by Blackwell.25 Out of this library several 
analogs were found, including iodophenyl HSL, 30 and compound 31, to be antagonists 
against all three bacteria .25 Additionally, bromophenyl HSL (33) and indole-HSL (32) 
were found to reduce biofilm formation of P. aeruginosa.26 Interestingly 34 acted as a 
potent agonist in V. fischeri although most other aryl analogs acted as antagonists.25 
Despite these successes AHLs are susceptible to hydrolysis by lactonases.14a Therefore 
analogs that lack the lactone moiety are more desirable.  Suga has synthesized analogs 
which have the lactone ring replaced with other cyclic structures.27 The cyclohexanone 
(36), cyclopentanol (35) and phenol (37) derivatives of 3-oxo-C12-HSL all acted as 
antagonist while cyclohexanol (38) was found to be an agonist of P. aeruginosa.27b Other 
structural alterations, for instance replacing the amide functionality with an amino-





Figure 1.6: Analogs of AIP1 and AIP2 
 Analogs of quorum sensing in gram-positive bacteria have primarily targeted S. 
aureus.  In this system oligopeptides are modified, cyclized and transported out of the 
cell.  These autoinducing peptides (known as AIPs) then bind the membrane bound 
protein AgrC which induces a phosphorelay mechanism and  controls virulence 
expression.  In S. aureus, four groups of AIPs are produced by different strains and are 
detected by specific AgrCs.29 It has been shown that AIPs of different groups bind and 
inhibit the response of the natural AIP.29 This cross-inhibition stimulated the evaluation 
of structural analogs of AIPs across groups (i.e. AIP-II analogs were tested on AgrC-1; 
Figure 1.6).29a Initial replacement of aspartate with alanine (AIP-1 D5A; 45) resulted in a 
potent inhibitor of all 4 AgrCs.30 Other variations such as 44 gave an inhibitor of AgrC-2 
and AgrC-4 only.30 Truncation of AIP-1 D5A (trAIP-1 D2A; 46) provided an equally 
potent inhibitor of AgrC-1-4.30 Likewise truncated AIP-II (41) was found to be a potent 
inhibitor across all four groups.30 Structure activity relationship (SAR) studies of this 
compound uncovered two additional derivatives, 42 and 43, which are more potent 






Figure 1.7: Compounds identified by high throughput screening 
 
 Other modulators of quorum sensing have been found by high throughput 
screenings (Figure 1.7). PD12 (47) and TP-5 (49) are inhibitors of AHL signaling in P. 
aeruginosa.32 TP-5 was the only antagonists amongst a series of structurally similar 
compounds all of which acted as agonists.32b LED209 (48) was found through high 
throughput screenings to inhibit Enterohaemorrhagic E. coli through binding to the 
membrane bound receptor QseC (for further details see p.6 and the indicated 
references).33 Competition with AHLs for binding to the membrane bound receptor 
protein, LuxN, in V. harveyi has recently been investigated by Bassler.34 Out of the 
30,000 compounds screened, 15 non-toxic candidates were identified most of which were 
structurally unrelated to AHLs (50 and 51).34 In a subsequent study, Bassler screened 




have the capacity to bind both membrane bound and cytoplasmic proteins.34 
Chlorothiolactone (52) was identified as an inhibitor of a human pathogen 
Chromobacterium violaceum, which uses the CviR as the LuxR-type cytoplasmic 
receptor.35 Further studies on chlorothiolactones, 53 and chlorolactone, 54, revealed that 
inhibition can occur through binding to CviR and inhibiting transcription or by 
preventing binding of CviR to DNA which also inhibits transcrition.35   
Though it has been shown that anti-quorum sensing chemotherapy is possible, the 
challenge to find a common target among many bacteria still remains. 
 
1.4 Autoinducer-2 mediate quorum sensing 
Most autoinducers are species-specific but there exists a universal autoinducer, 
AI-2, which has been detected in several species of bacteria.36  
 
Scheme 1.2: Equilibrium mixture of AI-2 compounds 
 
AI-2 is not a single compound but a collection of inter-converting compounds 55-
60 (Scheme 1.2).37 Once formed, DPD undergoes spontaneous rearrangements to give a 




DHMF; 56), (2R, 4S)-2,4-dihydroxy-2-methyldihydroxyfuran-3-one (R-DHMF; 59), (2S, 
4S)-2-methyl-2,3,3,4-tetrahydroxytetrahydrofuran (S-THMF; 57) and (2R, 4S)-2-methyl-
2,3,3,4-tetrahydroxytetrahydrofuran (R-THMF; 60).38 In the presence of borate salts, S-
THMF can form S-THMF-borate (58).37 It has been shown that different species of 
bacteria recognize different forms of DPD (See Figure 1.8); S. typhimurium detects R-
























Figure 1.9: Quorum sensing in enteric bacteria3a 
 
In enteric bacteria, AI-2 is internalized through the LsrABC transporter and 
phosphorylated by LsrK (Figure 1.9).39 Phosphorylated AI-2 (P-AI-2) acts as a substrate 
of the LsrR protein.39 In a non-quorum sensing state, LsrR represses the lsr operon.40 
When P-AI-2 binds to LsrR, the lsr operon is derepressed and the LsrR-regulated genes 
are expressed.39 LsrG, an enzyme encoded by the lsr operon, catalyzes the degradation of 
P-AI-2 into phosphoglycolic acid (PG) and an unknown C3 compound.41 It has been 
shown that the internalization of AI-2 by enteric bacteria interferes with the quorum 
sensing process of other bacteria.42 Similar internalization of AI-2 is executed in A. 
actinomycetemcomitans by the ribose binding protein, RbsB.43 In this organism 
phosphorylated AI-2 interacts with a two-component system consisting of QseBC, which 
controls biofilm formation and iron uptake.43  S. meliloti also internalizes AI-2 through a 






        
Figure 1.10: Quorum sensing in V. harveyi3a 
 
As previously mentioned, V. harveyi, a marine bacterium also uses AI-2 for 
signaling.45 V. harveyi uses quorum sensing to encode genes, which control 
bioluminescence and virulence.46 Under normal conditions (low cell density), LuxPQ acts 
as a histidine-kinase and initiates the phosphorylation of LuxU which subsequently 
phosphorylates LuxO (Figure 1.10).47 LuxO along with σ54 activates five small regulatory 
RNAs (sRNAs).11 48 These sRNAs along with the Hfq chaperone destabilize the 
transcriptional regulator, LuxR preventing its production.49 LuxR regulates the 
expression of genes responsible for bioluminescence and virulence.50 Therefore under 
normal conditions, LuxR is not present to induce the expression of genes responsible for 
bioluminescence and virulence factor production.50  In the quorum sensing state (high 
cell density), when AI-2 binds, LuxPQ acts as phosphatase and dephosphorylates LuxU 




activate bioluminescence and virulence genes.49 A similar phospho-relay is initiated upon 
AI-2 binding in V. cholerae but HapR, the homologue of LuxR, represses biofilm 
formation.51  
4, 5-Dihydroxy-2, 3-pentanedione (DPD; 55), the linear precursor of AI-2, is 
synthesized by the LuxS protein, which is highly conserved in both gram-positive and 
gram-negative bacteria.36, 45 Therefore it has been suggested that AI-2 functions as an 
interspecies signal unlike the intraspecies AHLs and oligopeptides.4a, 8 The luxS gene is 
present in over 60 species of bacteria and AI-2 production has been reported in many of 
these organisms.52, 3 Table 1.1 outlines a subset of these organisms and LuxS/AI’s role.  
Therefore drugs which target the LuxS/AI-2 quorum sensing system could have the 













Table 1.1:  Organisms which have the LuxS/AI-2 system 
Bacteria  Observed phenotype in LuxS 
mutants 
Complementation mode Ref 
Oral pathogens    
Streptococcus oralis Reduced mutualistic biofilm 
growth 
Synthetic DPD; 
Plasmid containing luxS gene 
53 
Streptococcus gordinii Downregulation genes required 
for carbohydrate metabolism; 
Reduced mixed biofilm formation 
Plasmid containing luxS gene 54 
Aggregatibacter 
actinomycetemcomitans 
Reduced biofilm growth  Partially purified DPD; Plasmid 
containing luxS gene 
43, 
55 
Porphyromonas gingivalis Reduced mixed biofilm growth; Synthetic DPD; 
Plasmid containing luxS gene  
54 
Streptococcus mutans Attenuated biofilm formation AI-2 producing bacterial strains 56 
Actinomyces naeslundii Reduced mutualistic biofilm 
growth 
Synthetic DPD; 
Plasmid containing luxS gene 
53 
Food-borne pathogens    
Salmonella typhimurium Inactive AI-2 internalization  In vitro synthesized AI-2; 
Plasmid containing luxS gene 
57 
Clostridium perfringens Reduced toxin production Culture supernatant 58 
Campylobacter jejuni No differentiation of genes (via 
microarray analysis) 
In vitro synthesized AI-2 59 
Bacillus cereus Normal biofilm formation In vitro synthesized AI-2* 60 
Listeria monocytogenes Increased biofilm formation  In vitro synthesized AI-2** 61  
Vibrio chlorae Increased biofilm formation Synthetic DPD* 62 
Vibrio angullarium Pigmentation Synthetic DPD 
63 
Vibrio ichthyoenter No change in biofilm formation 
or virulence 
N/A 64 
Vibrio vulnificus Decreased protease and increased 
haemolysin production 
Plasmid containing luxS gene 65 
Edwardsiella tarda  Reduced biofilm formation, type 
III secretion system gene 
expression and virulence 
Culture supernatant containing 
AI-2 
66 
Vibrio harveyi Reduced bioluminescence Synthetic DPD 46a 
Opportunistic pathogens    
Staphylococcus aureus Increased virulence factor 
synthesis 
Synthetic DPD  67 
Staphyloccous epidermidis Increased biofilm and enhanced 
virulence 
Plasmid containing luxS gene; 




Streptococcus intermedius Increased antibiotic susceptibility Synthetic DPD 70 
Streptococcus anginosus Increased antibiotic susceptibility Synthetic DPD 71 
Symbiotic bacteria    
Escherichia coli Reduced biofilm formation In vitro synthesized AI-2 
66 
Lactobacillus reuteri Increase biofilm thickness Purified AI-2** 
72 
Lactobacillus rhamnosus Decreased metabolism and 
biofilm formation 




   
Neisseria meningitidis Metabolic byproduct Culture supernatent 
74 




vitro synthesized AI-2 
Proteus mirabilis No effect on virulence or motility N/A 76 
Borrelia burgdorferi No effect N/A 77 
*addition of in vitro synthesized AI-2 caused a reduction in biofilm; **Failed to effect biofilm formation 
 
Despite the ubiquitous nature of AI-2 there is still some debate as to whether it is indeed 
used for signaling in all organisms which posses LuxS or if it simply acts as a metabolic 
byproduct of the methyl cycle.78, 79 In addition to DPD, LuxS also produces 
homocysteine, which is converted to cysteine and used in the biosynthesis of the essential 
amino acid, methionine. 80  Studies using LuxS mutants often show alterations in biofilm 
formation/architecture and/or virulence factor expression but due to the role of LuxS in 
metabolism it is often difficult to determine whether these alterations are the result of 
interfering with quorum sensing or due to the disruption of the active methyl cycle. 78 79  
Previous studies have relied on complementation of LuxS mutant strains with, plasmids 
containing luxS, culture supernatant containing AI-2, or in vitro synthesized DPD, 
partially puriefied AI-2 or synthetic DPD in attempts to decipher the role of the LuxS/AI-
2 system in bacteria. 78, 79  
In some organisms the role of AI-2 in pathogenesis is now clear.79 A luxS 
mutation in Vibrio vulnificus, an organism responsible for septicemia and wound 
infections, caused aberrant expression of virulence factors.65 Upon addition of culture 
supernatant containing AI-2, these virulence factors were restored to basal levels.65  In 
luxS mutants of Clostridium perfringens, the gram-positive pathogen responsible for 
gangrene, toxin production was restored to wild-type levels when culture supernatant 
containing AI-2 was added.58 However, this complementation strategy can be misleading 
since other components in culture supernatant cannot be ruled out as effecting virulence 




ulceration, gastric cancer and some types of gastric lymphoma, is controlled by AI-2 
mediated quorum sensing.75 Complementation with synthetic DPD in a luxS mutant 
restored motility through flagellar transcription whereas complementation with cysteine 
did not restore this phenotype. 75  In addition to phenotypes, transcriptome analysis has 
also been used to identify genes which are modulated in the presence of AI-2.  
Transcriptome analysis in Staphylococci reveals AI-2’s importance in metabolism and 
virulence.67, 69, 68  Transcriptome analysis in S. aureus revealed that deletion of the  luxS 
gene affected several metabolic enzymes as well as genes responsible for the production 
of capsular polysaccharide (CP), a virulence factor on bacteria cell walls which allow 
cells to evade phagocytes of the host immune system.67 Similarly transcriptome analysis 
of S. epidermidis luxS mutants showed metabolic genes being modulated but also 
modulation of pro-inflammatory and immune evasion factors.69, 68   
In addition to virulence factor expression, AI-2 has also been shown to control 
biofilm formation in several bacteria.74  A luxS mutant strain of Streptococcus oralis was 
unable to produce biofilm and grow mutualistically with Actinomyces naeslundii.53 This 
malfunction was restored by the addition of synthetic AI-2. Another oral pathogen 
responsible periodontal disease, Aggregatibacter actinomycetemcomitans, also lacked the 
ability to form biofilm and cause virulence in luxS mutant strains; partially purified AI-2 
was able to restore this activity.55 Finally biofilm formation and architecture was restored 
by in vitro synthesized AI-2 in Escherichia coli.66 In some organisms such as Vibrio 
cholerae, a human pathogen responsible for the gastrointestinal disease cholera62 and B. 
cereus, AI-2 signaling results in the repression of biofilm formation.60 Other phenotypes, 




example, antibiotic susceptibility was restored in a luxS mutant of Streptococcus 
anginosus71 and Streptococcus intermedius 70 after addition of synthetic DPD.   
A few examples point to AI-2 as a by-product of metabolism.81, 78, 79   Studies 
with the probiotic, Lactobacillus rhamnosus, reveal that neither growth nor biofilm 
formation was restored to wild type levels in luxS mutants with culture supernatant 
containing AI-2 or with chemically synthesized DPD.73 Though cysteine was 
successfully able to significantly restore growth and biofilm formation.73 Additionally, 
purified AI-2 was unable to restore biofilm in luxS mutants of Lactobacillus reuteri67 and 
Listeria monocytogenes.61 Transcriptome analysis in a luxS mutant of the human 
pathogen, Campylobacter jejuni, revealed that the differentiation of genes associated with 
metabolism, rather than quorum sensing, was responsible for this organism’s loss of 
motility.59 Also the addition of in vitro synthesized AI-2 had no effect on gene expression 
in this analysis, indicating that motility is affected by metabolic disturbance rather than 
quorum sensing.57 Similar transcriptional analysis using DNA microarrays in Neisseria 
meningitides indicated that the attenuation of virulence observed in luxS mutant was not 
due to quorum sensing as addition of culture supernatant containing AI-2 did not affect 
gene expression.81 Finally, the role of AI-2 in S. typhimurium has been questioned owing 
to the fact that complementation with chemically synthesized DPD was not able to 
restore biofilm formation.82 Cysteine and the other components of the active methyl cycle 
were also ineffective at restoring biofilm.82 Therefore it is unclear what caused biofilm 
perturbation in S. typhimurium.82 The relevance of quorum sensing in S. typhimurium has 
also been questioned because of the similarities in AI-2 processing with sugar 




AI-2 in S. typhimurium other than internalization.79 Other organisms for example 
Borrelia burgdorferi77 and Proteus mirabilis76 exhibit no difference in wild type versus 
luxS mutant strains indicating that LuxS may be present only for its role in the active 
methyl cycle.  The aforementioned examples reveal that not all organisms, which contain 
LuxS and produce AI-2 use it for quorum sensing.   
Though LuxS is important for metabolism and in some cases AI-2 has been shown to be a 
by-product of metabolism, it is clear that AI-2 can modulate virulence factor expression, 
biofilm formation and antibiotic susceptibility in several bacteria.74, 53, 71  Additionally, 
some organisms which do not have LuxS have been able to respond to exogenously 
added AI-2.44, 83 This could suggest that over time AI-2 as a by-product of metabolism 
became an indicator for some bacteria that other bacteria were present in their 
surroundings. Furthermore, AI-2 has been shown to form independently of LuxS from 
ribulose-5-phosphate.84 Therefore the designation of AI-2 as an interspecies signaling 
molecule is still valid as no other single molecule has been shown to be relevant to as 
many organisms as AI-2.8  
 
1.5 AI-2 inhibitors 
 




AI-2 is ubiquitous and chemotherapies which target this molecule could provide a 
broad-spectrum anti-infective agent.  Though inhibitors of the AI-2 mediated quorum 
sensing systems have not been rigorously pursued until recently. Initial attempts to inhibit 
AI-2 synthesis have involved the construction of analogs of the natural substrate of LuxS 
S-ribosylhomocysteine (Figure 1.11). 78, 84 Studies by Zhou revealed two active analogs: 
S-anhydroribosylhomocysteine, 61 and S-homoribosylcysteine, 62.85a These analogs 
were found to inhibit AI-2 synthesis but no other biological tests were conducted.84  
Other acyclic analogs of SRH (i.e., 63) were found to bind differently to the LuxS of 
different organisms including B. subtilis, V. harveyi and E. coli, although to varying 
extents.85b  LuxS inhibition would not be a useful target for anti-quorum sensing therapies 
though due to the fact that other metabolic processes are controlled by LuxS80 and the 
biological response of inhibitors could be the result of interfering with these processes 
rather than quorum sensing. 78, 79  
 
 
Figure 1.12: Structural analogs of AI-279, 86, 87, 88 
 
The inhibition of AI-2 via competition for receptors or processing enzymes has 




Initial studies looked at the natural compounds laurencione (64) and MHF (65) due to the 
structural similarities with the linear and cyclic forms of AI-2, respectively.86 Although 
both showed some activity they were not as effective at causing bioluminescence 
induction as AI-2 in V. harveyi.86 Synthetic efforts by Janda found that the enantiomer 
(4R)-DPD (66) was also less active than the natural molecule.86 Eventually new synthetic 
routes were published allowing for variations on the hydroxyl moieties of AI-2 analogs 
(68).87 Unfortunately, no biological tests have been reported for this analog although 
similar acetylated analogs were found to act identical to AI-2.89 An analog which 
replaced the hydrogens in the C1 methyl group of DPD with fluorines (trifluoromethyl-
DPD; 67) was found to be more active than the natural compounds (64, 65) or the 
enantiomer of DPD (66) in inducing bioluminescence in V. harveyi.88 With these initial 
results it became clear that AI-2 analogs often acted as less potent agonist of AI-2 
mediated processes rather as antagonists.  Subsequent studies by Janda identified butyl-
DPD (69) as a good inhibitor of β-galactosidase transcription in S. typhimurium although 
the mechanism of this inhibition was not revealed.90 Although butyl-DPD as well as 
propyl-DPD acted as antagonist in S. typhimurium they were also found to cause 






Figure 1.13: Structurally unrelated inhibitors of AI-2 QS91, 92, 63 
 
 
Other compounds have been screened which are structurally unrelated to AI-2 
(Figure 1.13). 91, 92, 63 The commercial compound pyrogallol (70) and its derivative (71) 
have been identified as a potent inhibitor of quorum sensing controlled-
bioluminescence.91 Likewise various boronic acids (72 and 73)92 inhibit bioluminescence 
at low concentrations although the toxicity of both the pyrogallol and boronic acid will 
likely prevent clinical use.  A new structural class of phenothiazine derivatives also have 
been found to inhibit AI-2 quorum sensing.93 Recently, a new set of compounds were 
screened for activity against V. harveyi and other vibrios.  LMC-21 (74)63 was found to 
be a potent inhibitor of biofilm formation in V. anguillarium and V. vulnificus as well as 
block V. harveyi infection of Artemia shrimp.63 Although structurally similar to SAM and 
SAH, the mode of inhibition of this nucleoside was found be through blocking the 




From the forementioned discussion of AI-2 inhibitors it is evident that there is a 
need for a more extensive development of structural analogs of AI-2 as these molecules 
are more likely to modulate quorum sensing in a diverse set array of bacteria. 
 
1.6 Objective, hypothesis and specific Aims 
The objective of this dissertation is to create a superior synthesis of AI-2 which 
facilitates the design of a large library of analogs.  Our hypothesis is that structural 
analogs will allow for probing into the promiscuity or specificity of quorum sensing 
proteins.  Also since AI-2 is a universal signaling molecule we hypothesize that analogs 
of AI-2 will have broad range applicability as modulators of quorum sensing or probes to 
identify new AI-2 receptors. 
The specific aims are as follows: 
1. To develop a new synthesis of AI-2 and construct analogs.  
 
Scheme 1.3: Retrosynthetic Analysis of AI-2 
2. To compare analog activities to AI-2 activity in several organisms by monitoring:  
a. Bioluminescence induction/inhibition in V. harveyi  
b. β-galactosidase production/inhibiton in E. coli and S. typhimurium 
c. Pyocyanin production/inhibition in P. aeruginosa 
3. To monitor the effect of AI-2 and analogs in mixed bacteria cultures which mimic 





1.7  Dissertation Outline 
Chapter 2 describes the newly developed synthesis of AI-2.  This chapter will 
demonstrate the ability of this new synthesis to obtain a library of diverse C1 analogs 
as well as C4 and C5 analogs.   
 Chapter 3 describes the evaluation of the newly developed analogs on V. harveyi, 
E. coli, S. typhimurium and P. aeruginosa.  This chapter also describes the evaluation 
of AI-2 and analogs on mixed cell cultures.   
 Chapter 4 will outline the conclusions, broader impact and future direction of this 
research 
 Chapter 5 provides the experimental procedure, spectroscopic characterization 






Facile synthesis of AI-2 and a diverse library of analogs 
 
 
2.1 Introduction: Discovering the chemical identity of AI-2 
AI-2 is now considered a universal quorum sensing molecule.  Initial genetic 
studies found that E. coli, S. typhimurium, V. cholerae, V. harveyi and E. faecium all 
contained the luxS gene which encodes for LuxS, the synthase enzyme for AI-2.46 The 
luxS gene is located near metK and Pfs, genes encoding proteins known to be involved in 
the active methyl cycle.36  
 
Scheme 2.1:  Biosynthesis of 4,5-dihydroxyl-2,3-pentadiene (DPD)  
 
The active methyl cycle is an important S-adenosylmethionine (SAM; 22) metabolic 
pathway which produces DPD and cysteine (Scheme 2.1).80  A methyltransferase 
removes a methyl group from the methionine moiety of SAM to form S-
adenosylhomocysteine (SAH; 75).36 Next, the Pfs enzyme removes the adenine group 
producing S-ribosylhomocysteine (SRH; 76).36 SRH is the substrate which is 




homocysteine.36 As homocysteine is known to be recycled to become cysteine and then 
methionine, it was proposed that DPD was an interspecies autoinducer responsible for 
light production in many organisms in addition to V. harveyi whereas HAI-1 (see Figure 
1.10; p. 4) is a species-specific signaling molecule.46 AI-2 can be synthesized in vitro 
using purifed proteins (Pfs and LuxS) and the required substrate (SAH; which is 
converted to SRH by Pfs).36 It can also be isolated as partial purified AI-2 using 
chloroform-methanol extraction or a boron affinity column.94  Despite these efforts a 
chemical synthesis of DPD, the precursor to AI-2, was needed to provide spectroscopic 
confirmation of the structure of AI-2.36  Ultimately a chemical synthesis of AI-2 would 
also provide the means to make analogs of AI-2, which could be used to perturb AI-2 
signaling in bacteria.   
 
2.2 Previous syntheses of AI-2  
Several groups were interested in chemical synthesis of AI-2/DPD80, 87, 92 yet 
despite its fairly simple framework, DPD is highly functionalized, prone to hydration and 
polymerization and is unstable to column chromatography.95 Therefore the chemical 









Scheme 2.2:  Janda's Synthesis of DPD Reagents and conditions: a) oxalyl chloride, DMSO, CH2Cl2; then 
Et3N; b) CBr4, Ph3P,CH2Cl2; c) tBuLi, MeI, THF; d) 60% AcOH; e) CH(OMe)3(neat), H2SO4(cat.); f) 
KMnO4, acetone, buffer(aq); g) H2O, pH 6.5 (K2HPO4/KH2PO4 (0.1 M), NaCl (0.15M)), 24 hr.95 
 
The first synthesis of AI-2, published by Janda in 2004, required seven steps 
(Scheme 2.2).95 The key step of Janda’s synthesis is a Corey-Fuch reaction to prepare 
alkyne 78.95 It was later observed that the acetal protecting group was difficult to deblock 
therefore compound 78 was converted to compound 79 and a subsequent potassium 
permanganate oxidation of alkyne 79 afforded diketone 80 (Scheme 2.2).95 Acidic 
cleavage of 80 was monitored by NMR and confirmed for the first time that AI-2 indeed 
existed as a mixture of the linear, DPD and cyclic products.95 The Mallaird reaction of 
the dione moiety of DPD and 1,2-phenylene diamine gave one single compound 






Scheme 2.3:  Semmelhack's Synthesis of DPD; Reagents and conditions: a) KIO4, K2CO3, H2O/CH2Cl2 
(76% yield) b) Ph3P, CBr4 (67%) c) i.nBuLi ii. H2O (79%) d) i. nBuLi ii. CH3I (64%/99%) e) cat. RuCl2 , 




In 2005, Semmelhack reported a synthesis of AI-2, which was similar to what 
Janda had reported.96 However Semmelhack utilized a  cyclohexylidene protecting group 
for the diol instead of an acetal group that was used by Janda (Scheme 2.3).96 Also, in 
Semmelhack’s synthesis, rhodium acetate/sodium periodate was used to oxidize the 
alkyne moiety into the diketone functionality instead of the harsher potassium 
permanganate reagent used by Janda.96 The major drawbacks of both Semmelhack’s and 
Janda’s syntheses are two-fold: 1) They both require several chromatographic separation 
steps which would not facilitate the rapid generation of analogs; 2) because the diol 
remains protected throughout their syntheses, the synthesis chemical probes of AI-2 
whereby one or both of the alcohol groups are functionalized is not possible by these 





Scheme 2.4:  Vanderleyen Synthesis of DPD a) NH(CH3)2, EtOH; b) CH2=C(CH3)MgBr, Et2O, 
THF; c) DOWEX 50X8-100, MeOH; d) O3, MeOH, Me2S.82 
 
Two additional syntheses of AI-2 were reported in 2005.82 The synthesis reported 
by Vanderleyden required five steps (Scheme 2.4).82 Key steps of  
Vanderleyden’s synthesis are the nucleophilic addition of a Grignard reagent to amide 88 
and a subsequent ozonolysis to access the dicarbonyl functionality of DPD (Scheme 
2.4).82 Cleavage of the acetal was performed using DOWEX resin.82 
 
 
Scheme 2.5:  Doutheau Synthesis. Reagents and conditions: (a) THF, DABCO (0.25 equiv), 0oC 
(b) TBAF (1 equiv), THF, rt. (c) O3, MeOH, -78oC, then DMS, -78oC to rt.89  
 
Lastly, Doutheau reported a three step synthesis of AI-2 using a Baylis-Hilman 
reaction and ozonolysis as key steps to access AI-2.89 Although the Doutheau synthesis is 
shorter than the previously reports, for AI-2 analogs whereby the starting material enone 






2.3 Previous syntheses of AI-2 analogs 
 
Scheme 2.6:  Synthesis of Trifluromethyl-DPD.88  
 
 Despite the obvious need for AI-2 analogs for biological testing, only a handful of 
AI-2 analogs had been synthesized and investigated for biological activities prior to this 
work.88  In 2006 Doutheau synthesized trifluoromethyl-DPD in six steps.88 In this work, 
the key Baylis-Hillman reaction was shown not to be widely applicable, as it resulted in 
an inseparable mixture of the desired product 96 and the aldehyde dimer 97 (Scheme 
2.6).88 Doutheau has also reported that the bis-(O)-acetylated AI-2 derivative is a stable 
analog of AI-2.87 In biological media the ester groups of this analogue are cleaved to 
release active AI-2.87 Additionally an AI-2 analog with a tertbutyl ester group was 
synthesized as well as ethyl-DPD and a 4,5-dihyroxyl-2,3-hexandione compound but 
these analogs were not tested for biological activity.89   
 From the foregoing discussions about AI-2’s synthesis and adaptation of the 
reported methodologies toward the synthesis of AI-2 analogs, it was evident that there 
was the need for a much simpler synthesis of AI-2 that will be amenable to the rapid 





2.4 Results: New facile synthesis of AI-2  
Scheme 2.7:  A new synthesis of AI-2.97 
 
We have developed a very simple synthesis of AI-2, which is amenable to analog 
synthesis.97 Our synthesis of AI-2 (Scheme 2.7) begins with the condensation of 
acyldiazomethane (102) with commercially available 2-(tert-butyl dimethylsilyloxy)-
acetaldehyde (91).97 The acyldiazomethane was formed via the reaction of acetyl 
chlorides with diazomethane.98 Nucleophilic addition of diazo compounds to aldehydes 
has previously been achieved through deprotonation of the diazo functionality by a strong 
base such as LDA or NaOH.99 Our initial attempts using LDA to deprotonate 
acyldiazomethane proved problematic, presumably due to the decomposition of the 
lithiated diazo intermediate.  Purification of the product was also challenging because 
several side products were formed.  In search of a milder method, we employed the 
DBU-catalyzed condensation of diazo compounds and aldehydes, first reported by 
Wang.100 This facile conversion was conducted at room temperature and gave the TBS-
protected hydroxydiazo: 5-(tert-butyldimethylsilyloxy)-3-diazo-4-hydroxypentan-2-one 





Scheme 2.8:  Resonance states of acyldiazo 
 
Subsequently a TBAF deprotection of the silyl group was conducted to give the 
diazodiol 103.97  Analysis by 13C NMR indicated that this diol remained in the linear 
form; there was an absence of signal between 100 and 120 ppm, which is indicative of 
lactols and a ketone peak at 192 ppm (See Experimental Section).  This is most likely due 
to the fact that the diazo carbonyl is less electrophilic because of resonance contributor 
106 (Scheme 2.8). Also an IR stretch of 2135 cm-1 indicated that the diazo functionality 
remained intact after treatment with TBAF.  During the course of our research we learned 
that we could conduct the TBAF deprotection without purification of the nucleophilic 
addition product.  We therefore performed the nucleophilic addition and deprotection 
successively and obtained a yield of 50% over two steps.97 The formation of compound 
103 set the stage for a facile oxidation to DPD. 
Due to its instability to column chromatography, in any successful synthesis of 
AI-2, the last step must involve the use of reagents that are readily removed.  For the 
oxidation of diazodiol 103 to DPD, we strategically chose the highly reactive dioxirane 
because it is volatile and easily removed.97 Dioxirane was prepared as a concentrated 
solution in acetone and added to the diazodiol 103.97 Upon disappearance of starting 




equilibrium mixture of compounds, as expected for the interconverting isomers of AI-2 










Figure 2.1: H1 NMR of equilibrium mixture of compounds derived from DPD 






Scheme 2.9:  Condensation of DPD with 1,2 phenylenediamine to form quinoxaline 
 
Finally the reaction of our synthetic AI-2 with 1, 2-phenylenediamine gave 
quinoxaline 107 as one species in 1H NMR (See Figure 2.2).97   
 
 
Figure 2.2: H1 NMR of quinoxaline derivative of AI-2 
Our concise synthesis differs from all other published approaches due to the clean final 
step.97 DPD synthesized using this method was stable at room temperature for at least 4 
weeks and stable upon refrigeration for several months. 
 
 








Figure 2.3: Library of diverse C1- analogs of AI-2.97, 101 
 
 With this facile synthesis in hand, we proceeded to synthesize 22 AI-2 analogs 
with branched, cyclic and aromatic as well as linear alkyl groups at the C1 position (108-
129; Figure 2.3).97  Janda’s AI-2 synthesis is not amenable to the synthesis of analogs 
with branched alkyl groups due to the difficulty of alkylation with secondary or tertiary 
groups.90 AI-2 analogs with branched and cyclic alkyl groups could provide important 
insights into the constraints of the active site in AI-2 receptor proteins such as LuxP and 




several commercially available acid chlorides, we were able to prepare diazo carbonyls 
with various alkyl groups via the reaction of diazomethane and acid chlorides.98 Desired 
alkyl groups whose acid chlorides were not commercially available were obtained from 
the carboxylic acid compounds. After the diazo carbonyl was acquired, synthesis of this 
diverse set of analogs followed the previously described method.97, 101 
Our new synthesis of AI-2 provided the route needed to access C1 analogs of AI-2 
(Compounds 108-129, see Figure 2.3). These were synthesized using various 
commercially available acid chlorides without difficulty and without the need for any 
alterations in our synthetic strategy.  The one-pot condensation-deprotection step was 
accomplished with moderate yields for analogs (108-129).   NMR analysis of these 
analogs (108-129) showed an equilibrium mixture of linear and cyclic analogs with 
exceptions being observed with neopentyl-DPD (118) and isobutyl-DPD (116).  The 
proton NMR of both neopentyl-DPD (118) and isobutyl-DPD (116) in D2O indicated that 
these analogs existed predominantly as linear forms.  Also a single species was observed 
in H1 NMR of DPD analogs in chloroform.  Differences in the equilibrium ratios of DPD 
and cyclic forms of different analogs may have the potential to affect the biological 










2.6 Synthesis of C4 and C5 analogs of AI-2 
 
Scheme 2.10:  New synthesis of diacetate AI-2 and analogs 
 
Although our synthesis of AI-2 is mild, due to the chemical reactivity of AI-2, 
purification cannot be achieved.  Therefore we endeavored to synthesize ester-protected 
AI-2 and analog derivatives, since this modification would allow purification to be 
preformed on silica gel.  Using our new methodology, we are able to synthesize the 
diacetate analog of AI-2 by treating diazodiol 130 with acetic anhydride to give 131 
(Scheme 2.10). Dioxirane oxidation of this compound gave diacetate DPD analog (132a) 
which remained in the linear confirmation.  Acetate protection was also conducted using 
select analogs (hexyl (132b) and isobutyl (132c)). These analogs would be used to 
observe the effect of protecting the diol on biological activity (See Section 3.10).  Also 
protection of AI-2 (methyl-DPD; 55) and hexyl-DPD (112) with  different ester groups 
were also conducted (see Supplementary S8).  Biological activity of these variants was 
also investigated (Section 3.10).  
 NMR analysis of ester-protected analogs was much cleaner than free DPD 
analogs.  As expected blocking the C4 and C5 hydroxyl groups prevents cyclization, 
therefore only one species was observed in both H1 and C13 NMRs spectra of the 




 Since AI-2 is known to dimerize at high concentrations, these ester-protected 
analogs could also provide a way to store AI-2 and analogs for prolonged periods without 
dimerization.  To test this hypothesis, ester analogs of AI-2 were stored at different 
temperatures for up to four weeks and biological testing was conducted on analogs to 
determine their stability under these conditions.  Results showed that both free and ester-
protected analogs maintained their biological profile after 4 weeks.  However, these 
acetate analogs were found to be slightly less active than free analogs (See 
Supplementary Figure S1).  Therefore the instability of AI-2 may be the result of harsh 
preparation methods by different synthetic routes or concentration. 
 
 
Scheme 2.11: Synthesis of deoxy-AI-2 analogs.101 
 
 Additional variations of the aldehyde used with our method provided 5-deoxy-
analogs of DPD (Scheme 2.11).101 Briefly diazocarbonyls were reacted with acetaldehyde 
to give 133.101 Dioxirane oxidation of 133 gave 134 as deoxy-analogs of DPD.101 




the two carbonyl groups are readily hydrated.  Synthesis of deoxy-AI-2 as well as other 
select analogs allowed the biological probing of the importance of the C5 hydroxyl group 
to be conducted (see Section 3.5).101  
 
2.7 Discussion 
 Six syntheses of AI-2 have been presented since 2004, yet several years lapsed 
before this research lead to the introduction of a library of analogs of AI-2. This is 
evidence that published syntheses are too lengthy and do not provide easy access to AI-2 
or analogs.  Elaboration of the C1 position of AI-2 using either the Janda or Semmelhack 
protocol requires an alkylation step via an SN2 displacement reaction.90 This places some 
constraints on the type of C1 analogs that can be readily obtained via these methods. 
Furthermore both Janda and Semmelhack’s methods protect the diol unit in AI-2 with an 
acetal protection and this does not allow easy variation at the C4 or C5 position.  
Additionally as evident in Janda’s synthesis the acidic cleavage of the diol moiety is not 
always straightforward.95 In Semmelhack’s synthesis although the cyclohexanone by-
product is shown not to effect cell growth; it remains to be seen if this by-product effects 
bioluminescence or can be internalized and/or processed by quorum sensing proteins.96 
Finally Doutheau’s synthesis though concise and keeps the diols free, requires starting 
enones that are not readily available.89 Moreover the Baylis-Hillman reaction can be 
problematic when attempting to synthesize analogs.88 Other recently published syntheses 








 In conclusion, our new synthesis of AI-2 is short and the most amenable to analog 
synthesis.101 Access to analogs of various shapes and sizes will allow the specificity or 
promiscuity of quorum sensing proteins to be deduced.  Not only does our synthesis 
allow for the rapid development of a large library of C1 analogs, but is also capable of 
constructing analogs with variations at the C4 and C5 position.  Furthermore this 
synthesis is shown to make stable AI-2 and analogs have been shown to remain active at 
various temperatures. (See Supplemental Figure S1)     This new synthesis has and will 
continue to aid in the discovery of new protein targets for anti-quorum sensing 




Chapter Three: Biological evaluation of analogs in V. harveyi, E. coli, S. typhimurium 
and P. aeruginosa 
 
 3.1 Bioluminescence 
 Quorum sensing was first discovered in the marine bacterium V. fischeri, which 
produces light when in a symbiotic association with the  Hawaiian Bobtail squid.4a It was 
observed that light production, known as bioluminescence, was highly dependent on cell 
density and researchers soon discovered that bacteria could coordinate gene expression 
through the detection of signaling molecules. This phenomenon was termed quorum 
sensing.102  
Bioluminescence is caused by an enzyme-catalyzed reaction, which is controlled 
by the lux (luciferase) gene operon.46b Light is produced by the oxidation of a reduced 
flavin mononucleotide (FMNH2) reacting with molecular oxygen and a fatty aldehyde.46b 
This reaction results in the emission of blue-green light at 490 nm.46b Bioluminescence 
occurs in several other species of the Vibrio genera as well as the Xenorhabdus, 
Photobacterium, and Shewanella generas.46b Different substrates and proteins control 
light production in each bioluminescent organism with the only similarity being the use 
of molecular oxygen.46b The lux operon is usually made up of luxCDABE genes required 
for the synthesis of the luciferase (luxAB) and aldehyde substrate.46b The aldehyde 
substrate is formed via a fatty acid reductase encoded by luxCDE required to convert 
polypeptides to the fatty aldehyde.46b The lux operon of V. fischeri consists of 
luxRICDABEG with the additional genes: luxR, luxI and luxG.46b luxG has been proposed 




mononucleotide.46b We now know that luxI and luxR encode the synthase (LuxI) and 
receptor (LuxR) of the AHL autoinducer.9   After quorum sensing was first discovered in 









Scheme 3.1: Mechanism of bioluminescence production with riboflavin as the luciferin 
 
V. harveyi, another marine organism which uses quorum sensing to regulate 
bioluminescence, uses a quorum sensing system that greatly differs from that of V. 
fischeri and other gram-negative bacteria. In V. harveyi the lux operon consists of 
luxCDABEGH, with the additional gene luxH encoding for the synthesis of the riboflavin 
precursor, 3,4-dihydroxy-2-butanone-4-phosphate.46b This indicates that riboflavin is the 
luciferin (luciferase substrate) in V. harveyi.46b Interestingly, the lux operon of V. harveyi 
does not contain genes encoding for LuxI and LuxR.11 This is due to the fact that V. 
harveyi does not use the LuxI-LuxR system for quorum sensing like V. fischeri.11  Instead 
a region separate from the luxCDABEGH operon has been identified in V. harveyi, which 
also controls the luminescence phenotype. This region contains the regulatory gene luxR 




factor required for expression of the luxCDABEGH operon.46b LuxR acts as both an 
activator and repressor of quorum sensing-controlled processes; it activates 
bioluminescence, while repressing type III secretion factors. 11, 45a LuxR is controlled by 
a phosphorelay mechanisms involving a series of proteins which are switched on at high 
cell density (See Section 1.4).11  
 
Figure 3.1: Dimer of 2 LuxPQ complexes bound to 2 molecules of AI-2 
(LuxP (green) bound to AI-2 and periplasmic domain of LuxQ (red);  LuxP’(cyan) bound to  
AI-2 and periplasmic domain of LuxQ’ (magenta))  
 
As previously described, the S-THMF-borate isomer is the active AI-2 found 
bound to LuxP in V. harveyi.37 The presence of boron is likely due to the marine 
environment in which V. harveyi resides, where boron concentrations can reach up to 0.4 
mM.11 The AI-2 pathway of V. harveyi is quite unique because its receptor exists as a 
dimer (LuxPQ).47a Crystallography and mutagenesis of this LuxPQ complex have been 
studied and much insight is now known about the role of this interesting pair in 




low cell density.47a Also certain contacts intrinsically exist between LuxQ and LuxP, 
which inhibits the conversion of LuxQ from kinase to phosphatase.47a  These contacts are 
disrupted upon binding of AI-2.47a Additionally, it has been revealed that two LuxPQ 
dimers merge in the presence of AI-2 and exist at a 140 degree angle to each other.103 The 
formation of this tetramer results in the release of LuxQ, switching it from kinase to 
phosphatase, and therefore turning quorum sensing “on”.103 Since these conformational 
changes are vital for AI-2 to mediate quorum sensing, it may be possible to design small 
molecules which interfere with these changes and perturb the signaling pathway.   
LuxP and analogous phosphorelay mechanisms are found in most Vibrios11  Also 
LuxR homologs have been discovered in V. cholera (HapR)104, V. angullarium 
(VanT)105, V. parahaemolyticus (OpaR)106, V. vulnificus (SmcR) 107 and V. fischeri 
(LitR)108. It is likely that homologous proteins exist in organisms in which quorum 
sensing circuits have not yet been defined. Therefore investigations into how small 
molecules modulate the bioluminescence production of V. harveyi by targeting LuxR and 












3.2 Synergistic agonism in V. harveyi 
Table 3.1: V. harveyi strains and genotypes47b,102 
 
V. harveyi strains Relevant genotype and/or property 
BB120 Wild type 
BB170 Wild type luxN::Tn5 (sensor 1-, sensor 2+); AI-
1+, AI-2+ 
MM32 luxN::Tn5; luxS::Tn5 (sensor 1-, sensor 2+); 
AI-1+, AI-2- 
BB886 Wild type luxPQ::Tn5 Kan 
BB721 Wild type luxO::Tn5 
 
  
 V. harveyi bioluminescence induction is often used as a reporter of AI-2 signaling 
activity.102 After the development of our facile synthesis, we sought to investigate how 
C1 analogs of different sizes and shapes modulate the quorum sensing circuit of V. 
harveyi through the monitoring of bioluminescence induction.97  Initial screenings for 
bioluminescence induction in V. harveyi were conducted on a diverse subset of the entire 
C1 analog library created.97 Since the LuxN/HAI-1 pathway is the dominant signaling 
pathway in V. harveyi109 it is important to suppress detection of HAI-1 by LuxN.  Also in 
order to control the amount of AI-2 in this model system, AI-2’s synthase, LuxS, must be 
inactivated.  Therefore a LuxN, LuxS double mutant strain (designated MM32) was used 
for testing. At high concentrations (50µM) only ethyl-DPD (108; Figure 2.3) and 
cyclopropyl-DPD (119; Figure 2.3) were able to induce bioluminescence after 8 hours 
albeit to a 10-fold lower degree than AI-2 (Figure 3.1a).97 The other analogs tested were 




concentrations (2µM) none of the analogs significantly induced bioluminescence (Figure 
3.1b).97 Ironically in the presence of 12nM AI-2, analogs were found to synergize the 
action of AI-2.97 Ethyl-DPD (108; Figure 2.3) and cyclohexyl-DPD (122; Figure 2.3) 
gave the most pronounced synergistic agonism causing 4.3-fold and 9.1-fold activation, 
respectively.97 The remaining analogs gave moderate enhancement: propyl-DPD (109; 
2.6 fold), butyl-DPD (110; 2.7 fold), isopropyl-DPD (114; 2.4 fold), tert-butyl-DPD 
(115; 2.9 fold) and cyclopropyl (119; 3.1 fold) (See Figure 2.3 for structures).97 Other 
researchers90, 110 have reported similar synergistic agonism however the observation of 
synergism in analogs of a range of shapes and sizes suggest promiscuity in the quorum 







Figure 3.2: a) Bioluminescence induction in V. harveyi MM32 (at 8hrs) by addition of 2µM analog, 12nM 
AI-2 and 100µM boric acid b) Bioluminescence induction in V. harveyi MM32 by addition of 50µM 
analogs and 100µM boric acid.97 
 
In order to shed light on the mechanism of synergistic agonism by AI-2 analogs,  
bioluminescent strains with deletions in select proteins involved in signal transduction in 
V. harveyi have been tested (For a detailed scheme of the AI-2 signaling pathway in V. 
harveyi see Supplementary Figure S11, p121).  V. harveyi BB886 is a LuxQ mutant strain 
which cannot respond to AI-2.102 Therefore any modulation observed in this strain would 
be the result of analogs acting on the AI-1 pathway.  Since analogs were not able to 
induce bioluminescence in this strain, it is probable that synergistic agonism is derived in 
the AI-2 pathway.  (See Supplemental Figure S2) Another possible target of synergistic 
bioluminescence is the transcriptional regulator LuxR.  Small molecules have been 
shown to bind LuxR and destabilize its interaction with the lux operon.16 Therefore it is 




resulting in synergism with AI-2.  V. harveyi BB721, is a LuxO mutant strain and since 
LuxO indirectly represses luminescence through LuxR this strain is always bright.47b If 
C1 analogs target proteins downstream of LuxO, incubation with V. harveyi BB721 
should give the same synergistic response in this mutant (BB721).  No synergism was 
observed with C1 analogs in this strain (See Supplemental Figure S3). Although these 
observations suggest that the target of C1 analogs is upstream of LuxO, more 
experimentation is needed to definitively determine the mechanism of synergistic 
agonism.   
 
3.3 Discussion-V. harveyi 
Synergistic agonism by C1 analogs of AI-2 provides further insight into the well 
known quorum sensing circuit of V. harveyi. Mutant bioluminescent strains showed that 
deletion of LuxQ abolished the observed synergisms.  Also a lack of response following 
the mutation of the response regulator, LuxO, suggests that analogs do not bind LuxR. 
These findings point to the action of C1 analogs being at the LuxPQ level.  Analogs are 
unable to induce bioluminescence on their own. This may lead to the assumption that 
these molecules do not bind LuxPQ effectively.  However it is possible that analogs bind 
LuxPQ allosterically and sensitize LuxP to AI-2. Mutagenesis at the LuxP:LuxQ 
interface resulted in sensitizing LuxP to lower AI-2 concentrations.47a Therefore, it is 
possible that C1 analogs similarly bind to one active site of the LuxPQ dimer while AI-2 
binds to the other active site.  The conformational change that results from this hetero-
ligand binding probably leads to a more efficient kinase activity by LuxQ.  Future 





3.4 Quorum sensing in enteric bacteria 
Table 3.2: Enteric bacteria strains and genotypes 101,39 
E. coli strains Relevant genotype and/or property 
W3110 Wild type 
LW7 W3110 ΔlacU160-tna2  
ΔluxS::Kan 
ZK126 W3110 ΔlacU169-tna2  
LW8 ZK126_lsrR::Kan 
LW9 ZK126 Δ(lsrACDBFG)::Kan 
SH3 W3110 ΔlacU160-tna2  
ΔluxS ΔlsrK ::Kan; Cm 
S. typhimurium strains  
MET708 rpsl putRA :: Kan-lsr-lacZYA luxS::T-POP 
MET715 rpsl putRA :: Kan-lsr-lacZYA  
 
In addition to bioluminescence induction in Vibrios, the AI-2 signaling pathways 
of enteric bacteria (i.e. E. coli and S. typhimurium) are well characterized.41 The 
lsrACDBFGE operon controls the expression of the proteins involved in the transport and 
processing of AI-2 in these organisms.39 The lsr operon is AI-2-dependent hence the 
designation LuxS-regulated (lsr).39 In addition to transport proteins, the lsr operon 
divergently transcribes genes which encode LsrK, the AI-2 kinase and LsrR, the 
transcriptional repressor.39 LsrR plays a vital role in the biofilm architecture of E. coli.108 
It was reported that a LsrR mutant strain of E. coli produced biofilm which was 




into quorum sensing controlled expression of the lsr operon could contribute to the 
development of anti-biofilm treatments through small molecules which target LsrR. 
 
3.5 Inhibition and processing in enteric bacteria  
 In addition to V. harveyi bioluminescence, we investigated the effect of diverse 
linear and branched C1 analogs on the uptake and processing of AI-2 in enteric 
bacteria.101 Since lsr is under AI-2 mediated- quorum sensing control, we used lsr-lacZ 
reporter strains to observe modulation of β-galactosidase production by AI-2 analogs.  
The lacZ gene expresses the enzyme β-galactosidase, which in nature cleaves lactose into 
glucose and galactose. lacZ is often fused to gene operons where an analog of lactose, 
called o-nitrophenyl-β-galactoside (ONPG), is used as a colometric indicator of operon 
activity.111 Once the target operon is activated and lacZ is expressed, β-galactosidase is 
produced.111 If  ONPG is introduced into the system, it is cleaved and generates o-
nitrophenol.111 O-nitrophenol is yellow and has a UV absorbance at 420 nm.111 Therefore 
the intensity of o-nitrophenol detected is proportional to the amount of β-galactosidase 
produced.  Since the lsr operon is under quorum sensing control, bacterial strains 
containing the lsr-lacZ fusion, produces β-galactosidase in response to AI-2.  Conversely 
small molecules which interrupt AI-2 mediate lsr expression will not produce β-
galactosidase. 
Initial results using LuxS mutant strains in both E. coli and S. typhimurium 
showed that only ethyl-DPD (110; Figure 2.3) was able to activate transcription of lsr on 
its own101 (See Supplementary Figure S5). Next we tested our analogs for their ability to 




(LuxS+) several analogs were able to compete with AI-2 in E. coli including all linear 
analogs with chain-length greater than 2-carbons (propyl-DPD (109), butyl-DPD (110), 
pentyl-DPD (111), hexyl-DPD (112), and heptyl-DPD (113); see Figure 2.3 for 
structures) and several branched analogs (isopropyl-DPD (114), isobutyl-DPD (116), 
secbutyl-DPD (117), neopentyl-DPD (118)).101 Ironically in the LuxS+ S. typhimurium 
reporter strain, fewer linear analogs  (butyl-DPD; 110 and to a lesser extent propyl-DPD; 
109) and a single branched analog (isobutyl-DPD; 116) were able to antagonize AI-2 
signaling.101 Therefore isobutyl-DPD (116)was identified as a potent inhibitor of both E. 
coli and S. typhimurium quorum sensing.101 Identical results emerged when exogenous 







Figure 3.3: AI-2 dependent β-galactoside production in E. coli ZK126 pLW11 and S. 
typhimurium MET708 (both luxS+) in response to a) linear analogs and b) branched and deoxy 
analogs.101 
 
To further understand the mechanism by which analogs cause inhibition of 
quorum sensing, we tested their ability to be processed by the AI-2 internalization and 
phosphorylation proteins, LsrB and LsrK, respectively.101  A lacZ reporter strain lacking 
the transporter, LsrB, was tested for activity in the presence of AI-2 and analogs in E. 
coli.101 Ironically, both agonists (methyl-DPD; 55 and ethyl-DPD; 108) and antagonists 
(C3 and greater linear; branched analogs) remained effective in modulating quorum 
sensing in the absence of the AI-2 transporter (See Supplementary Figure S6).101 It is 
possible that analogs are able to freely diffuse into the cell or use alternative transporters.  




conducted to test whether analogs were able to be phosphorylated by LsrK.101   TLC 
shows that all DPD-analogs are phosphorylated whereas deoxy-analogs, which lack a 
hydroxyl group at the C5 position (See Section 2.6 for structure of deoxy-analogs) are not 
phosphorylated (Figure 3.4).101 This confirms Bassler’s assignment of phospho-AI-2 as 
having the phosphate group on the C5 hydroxyl rather than the C4 hydroxyl.41 
Interestingly, even analogs which do not antagonize AI-2 signaling are able to be 
phosphorylated by LsrK.101 Therefore phosphorylation must not be the only determinant 
which controls inhibition of the lsr operon.   
 
Figure 3.4: a) Phosphorylation of DPD by LsrK in the presence of ATP b) Representative radioactive TLC 
analysis of LsrK mediated phosphorylation.  ATP, AI-2, Butyl-DPD, Isobutyl-DPD and deoxy-Isobutyl 





Binding of phospho-AI-2 to the transcriptional repressor, LsrR is key to the 
expression of genes in the quorum sensing system of enteric bacteria.41, 110 Phospho-AI-2 
has been shown to bind LsrR and subsequently destabilize its interaction with the lsr 
operon promoter region therefore de-repressing the operon.112 We predict that it is the 
phosphorylated form of ethyl-DPD (108), which causes agonism through destabilization 
of the LsrR-operon complex.  To support this notion, reporter strain lacking LsrK did not 
show agonism (Figure 3.5).101   
 
 
Figure 3.5: AI-2 dependent β-galactoside production in E. coli SH3 (LsrK-, LuxS-) and E. coli 






Figure 3.6: AI-2 dependent β-galactoside production in E. coli ZK126 (LsrR+) and E. coli LW8 
(LsrR-) in response to methyl-DPD (AI-2), butyl-DPD, isobutyl-DPD and deoxy-isobutyl-DPD.101 
 
 
Likewise, phosphorylated forms of antagonists probably bind LsrR and stabilize its 
interaction with the lsr operon, sustaining its repression of quorum sensing-controlled 
genes.  Screening of the most potent inhibitors (butyl-DPD; 110 and isobutyl-DPD; 116) 
in strains lacking the LsrR repressor revealed that inhibition was not observed (Figure 






Figure 3.7: a) AI-2 dependent β-galactoside production in S. typhimurium MET708 b) AI-2 dependent 
bioluminescence production in V. harveyi BB170 and c) Flow cytometry analysis of AI-2 dependent GFP 
induction in E. coli W3110 pCT6 (all strains are luxS+) in response to isobutyl-DPD and isopropyl-DPD.101 
 
 It is well known that AI-2 signaling in one species can be detected and interfere 
with the quorum sensing network of another unrelated species.42 Thus we postulated that 
inhibitors of AI-2 signaling would be able to perturb several quorum sensing systems 
simultaneously.  To test this hypothesis, we examined our most potent analog isobutyl-
DPD (116), in a tri-species synthetic ecosystem.101 This synthetic ecosystem was 
strategically designed so that the response of each organism to AI-2 was uniquely 




β-galactoside production in S. typhimurium MET708, GFP induction in E. coli W3110 
pCT6, and bioluminescence induction in V. harveyi BB170.101 As anticipated isobutyl-
DPD (116) was a potent inhibitor of E. coli GFP induction and S. typhimurium β-
galactosidase production in the synthetic ecosystem (Figure 3.7a and 3.7c).101 
Surprisingly isobutyl-DPD (116) was also able to inhibit V. harveyi bioluminescence 
(Figure 3.7b).101 Although C1 analogs of AI-2 are known to cause synergistic agonism of 
bioluminescence in AB media97, it has been shown that once a quorum is already formed 
they act as antagonists.101 This antagonism is only observed in LM media.101 Since 
bioluminescence is highly dependent on environment, we assume that components of the 
media may change the observed effect of analogs.  Therefore isobutyl-DPD (116) has 
emerged as a broad-spectrum inhibitor of quorum sensing.   
 While isobutyl-DPD (116) showed broad inhibition, isopropyl-DPD (114) was 
found to be a selective inhibitor of E. coli which did not effect S. typhimurium (Figure 
3.7a and 3.7c).101 Selectivity is of great benefit when pathogenic bacteria exist in a niche 
where symbiotic organisms exist.  Similar to isobutyl-DPD, isopropyl-DPD was also 
found to inhibit V. harveyi bioluminescence (Figure 3.7b).101 Therefore we have found 
both a broad and a selective inhibitor which were effective in a mixed culture 
environment.101   
 
3.6 Discussion- E. coli and S. typhimurium 
Three proteins have been identified as key AI-2 signaling in enteric bacteria, 
LsrB, LsrK and LsrR and may act as checkpoints when AI-2-like molecules are 




mutant that analogs are able to enter the bacterial cell through diffusion or alternative 
transporters.101 AI-2 has been shown to be transported by the ribose binding protein RbsB 
in other organisms.55 Therefore it is plausible that AI-2 analogs also use this apparatus as 
an alternative entry into the cell or perhaps they can freely diffuse into the cell.101 For the 
second checkpoint, in vitro phosphorylation was shown in all analogs.101 Moreover 
deoxy-analogs were not phosphorylated indicating that the hydroxyl group on the C5 
position is necessary for phosphorylation.101 Also we’ve confirmed that phosphorylation 
is required for gene expression, as the LsrK mutant was unable to activate the lsr operon. 
101 From this observation we can assume that it is the phosphorylated form of analogs 
which cause agonism or antagonism of the lsr operon. 101 Finally lack of inhibition in 
LsrR mutants indicate that LsrR is the target of C1 analogs and the various biological 
profiles of the analogs are likely due to varying binding affinities for LsrR.  We predict 
that the C1 alkyl chains interact with LsrR and cause the protein to bind to the DNA 
promoter region of the lsr operon to different extents. 101 Since a minimum 3-carbon 
chain length is required for antagonism we can assume the side chain binds to a 
hydrophobic region and causes a stronger LsrR-DNA complex to form. 101 In contrast to 
AI-2 (methyl-DPD; 55) and ethyl-DPD (108) cause LsrR not to bind and therefore de-
represses the operon. 101   
The differences observed in quorum sensing modulation in S. typhimurium and E. 
coli indicate that subtle differences may exists which make the S. typhimurium system 
more robust.  Interestingly several linear and branched analogs were able to repress lsr 
transcription in E. coli while only butyl- and isobutyl-DPD were effective in S. 




are homologous.101 Alignment studies have shown that LsrK and LsrR proteins in these 
organisms share 82% and 77% homology, respectively.101 Also the E. coli LsrR binding 
site showed 83% homology to the S. typhimurium promoter region.101 In addition 
predicted secondary and tertiary structures show similar folds for these organisms (Figure 
3.8).101 Further studies are needed to determine why these systems show divergent 
response to C1-analogs.   
 
Figure 3.8: Predicted tertiary structures of the LsrR proteins of S. typhimurium (green) and E. coli 
(cyan) provided by ESyPred3D101 
 
The observation that analogs of AI-2 can be either broad- or selective-inhibitors in 
mixed cultures is medically relevant since bacteria rarely exist in isolation.113  Therefore 
quorum sensing targets which remain effective in mixed cultures that most resembles 
natural environments are valuable.  Overall, linear and branched analogs gave much 
insight into the ability of AI-2 like molecules to be processed by the AI-2 machinery of 





3.7 Pseudomonas aeruginosa 
 P. aeruginosa is an opportunistic pathogen which causes biofilm-related lung 
infections in cystic fibrosis patients.114 P. aeruginosa quorum sensing uses the typical 
LuxI-LuxR-type system found most often in gram-negative bacteria.7 Quorum sensing 
has been shown to control biofilm in this organism as mutant strains with alterations in 
the quorum sensing pathway are deficient in biofilm formation.114 Biofilm formation was 
restored upon addition of the signaling molecule, N-3-oxo-dodecanoyl-homoserine 
lactone (See Figure 1.1; 6).114 This observation suggests that N-3-oxo-dodecanoyl-
homoserine lactone (6) is vital for biofilm formation and that small molecules which can 
compete with this signaling molecule may be able to prevent biofilm formation.114 
Several small molecules analogs of AHLs have been identified which modulate 
Pseudomonas biofilm formation yet they face solubility and stability issues.25-26  
Therefore there is a need for structurally diverse small molecules which target quorum 
sensing and are able to clear P. aeruginosa associated biofilm infections. 
AI-2 is not synthesized in P. aeruginosa nor have any AI-2 receptors been identified in 
this organism.83 Genetic analysis has shown that AI-2 up-regulates some genes required 
for Pseudomonas pathogenesis.83 This is an interesting phenomenon as AI-2 has been 
suggested to be a universal signaling molecule and therefore able to be sensed by an array 
of bacteria.  C1 analogs of AI-2 contain side chains which resemble the side chains found 
in AHLs.  It has been suggested that these analogs freely diffuse through the cell in a 
manner similar to how AHLs diffuse into the cells and directly bind the LuxR-type 




analogs are AI-1-like and therefore able to affect the AI-1 pathway of gram-negative 
bacteria in addition to the AI-2 pathway of enteric bacteria, this dual action is another 
means of universally affecting quorum sensing.   
 
3.8 P. aeruginosa pyocyanin production modulation 
Table 3.3: P. aeruginosa strains, genotypes and references 
P. aeruginosa strains Relevant genotype and/or property 
PAO1 Wild type 
 
 AHL analogs of various shapes and sizes have been found to modulate quorum 
sensing and biofilm formation in P. aeruginosa.10 Likewise we decided to screen our 
entire library of C1 analogs including cyclic and aromatic (See Figure 2.3; 108-129) on 
P. aeruginosa. 
 






Figure 3.10: Pyocyanin production in P. aeruginosa PAO1 in response to methyl-DPD, ethyl-
DPD, heptyl DPD, isobutyl-DPD, cyclopentyl-DPD and phenyl-DPD 
 
The effect of analogs on the production of a virulence factor, pyocyanin, is an 
interesting method to evaluate the effect of small molecules on this quorum sensing-
controlled process.  Pyocyanin is an aromatic compound which absorbs at 540 nm and 
produces a blue-green pigment (Figure 3.9).115  In the wild-type strain PAO1, only a few 
C1 analogs were found to reduce pyocyanin production.  Several linear analogs 
moderately inhibit pyocyanin production while some cyclic and aromatic analogs are 
more effective.  A panel of analogs are shown in Figure 3.10.  Heptyl-DPD (112), 
cyclopentyl-DPD (121) and phenyl-DPD (125) (see Figure 2.3 for analog structures)  
were the most effective modulators of pyocyanin production (See Supplementary Figure 
S6 for biological profile of analogs in P. aeruginosa).   
 In addition the cyclic and aromatic analog subsets were screened in E. coli and S. 




























































none of the cyclic or aromatic analogs were able to induce gene expression on their own 
(See Supplementary Figure S7).  Next the analogs were screened in the presence of 
















































































































Figure 3.11: AI-2 dependent β-galactoside production in E. coli LW7 and S. typhimurium 
MET715 (both luxS-) in response to 40 µM synthetic DPD and a) cyclic analogs and b) aromatic 
analogs. 
 
Of the cyclic analogs only cyclopentyl-DPD (121) significantly antagonized AI-2 activity 
while cyclobutyl-DPD (120) gave minimal inhibition in E. coli (see Figure 3.11).  Larger 
cyclic analogs (cyclohexyl-DPD (122), CH2-cyclohexyl-DPD (124) and cycloheptyl-
DPD (123); see Figure 2.3) all did not give significant knockdown.  Therefore AI-2 
processing enzymes may be unable to accommodate large groups at the C1 position 
greater than cyclopentyl-DPD (121).  Also since 5-membered rings are more flexible than 
3- and 4- membered rings, a desired conformation may be required for inhibition that is 
inaccessible to the more strained cyclopropyl-DPD (119) and cyclobutyl-DPD (120) 





















































































or S. typhimurium including the 5-membered aromatic analog, furanoyl-DPD. It is likely 
that some degree of flexibility is required at the C1 position for analogs to be processed, 
which the flat aromatic compounds lack.  Cyclopentyl-DPD (121) was not effective at 
inhibiting S. typhimurium lsr expression. This is consistent with our previous finding that 
the two enteric bacteria show differing levels of susceptibility.101  Further studies and 
molecular modeling will be conducted to determine if cyclic and aromatic groups are 
incompatible with AI-2 processing enzymes due to their bulkiness and rigidity. 
 
 
Figure 3. 12: a) AI-2 dependent β-galactoside production in S. typhimurium MET708 b) Pyocyanin 
production in P. aeruginosa PAO1 and c) Flow cytometry analysis of AI-2 dependent RFP induction in E. 
coli W3110 pCT6 dsRed (all strains are luxS+) in response to isobutyl-DPD, phenyl-DPD and a cocktail 





 A new synthetic ecosystem was constructed using E. coli, S. typhimurium and P. 
aeruginosa.  As previously discussed, in order to decipher the response of each bacterium 
different reporters were used:  AI-2 induced β-galactoside production in S. typhimurium 
MET708, pyocyanin production in P. aeruginosa PAO1 and AI-2 dependent RFP 
induction in E. coli W3110 pCT6 dsRed. Previously isobutyl-DPD (116) was found to be 
an inhibitor of E. coli, S. typhimurium and V. harveyi yet it is not able to inhibit 
pyocyanin production.  Phenyl-DPD (125) is a potent inhibitor of pyocyanin production, 
therefore we developed a cocktail containing these two complementary analogs.  This 
cocktail was able to knockdown quorum sensing in all three organisms of this new 
synthetic ecosystem.  The analog cocktail approach is a new avenue to simultaneously 
perturbing the quorum sensing system of several organisms to be further explored.      
 
3.9 Discussion- P. aeruginosa 
These results show that expanding the diversity of groups at the C1 position of 
AI-2 to include cyclic and aromatic groups allow for diverse bacteria to be targeted. In 
addition to the 3-carbon length minimum previously identify for E. coli inhibition, cyclic 
analogs reveal that a five-membered ring (cyclopentyl-DPD; 121) may be the optimal 
ring size able to effect AI-2 processing enzymes.  Also smaller rings and aromatic 
analogs suggest that some degree of flexibility is required for inhibition.   
Although P. aerguinosa is a part of the human microflora, lung infections caused 
by these pathogens are difficult to treat due to robust biofilm.115 AHL analogs which have 
been shown to perturb quorum sensing regulated biofilm formation are known to have 




native defense enzymes.14b, 116 AI-2 analogs, which are able to interfere with the AI-2 
pathway in enteric bacteria as well as the AI-1 signaling pathway in organisms such as P. 
aeruginosa, would be a valuable addition to the arsenal of quorum sensing small 
molecules currently available.  
 
3.10 Ester-protected AI-2 and analogs 
  Although ester-protection may be desired for the stability and purification of AI-2 
and analogs, it remains to be seen if these derivative will behave similarly in biological 
systems.  Acetate-protected AI-2 has been shown to induce bioluminescence in a manner 
similar to free AI-2.87 It is therefore hypothesized that analogs of AI-2 with ester 
protecting groups would also act in a manner synomonous to the free DPD analog. Also 
different ester protecting groups may offer varying levels of bioactivity.  Ester protected 
pro-drugs of AI-2 and hexyl-DPD were synthesized and first screened in V. harveyi 
MM32 (LuxN-, LuxS-).  Also ester-protected analogs did not inhibit bacterial growth 
(see Supplementary Figure S8). We found that ester analogs of AI-2 were able to induced 
bioluminescence to a significant extent (Figure 3.13a; black bars) were as ester-protected 
hexyl analogs were not able to induce bioluminescence in their own (Figure 3.13b; white 
bars).  This would be expected since C1 analogs do not induce bioluminescence on its 
own (with the exception of ethyl-DPD; 108).  




       
 
Figure 3.13:  Bioluminescence induction in V. harveyi MM32 (LuxS-) in response to various ester 
protections on AI-2 and hexyl-DPD 
 
Next, analogs were screened for synergistic agonism.  Synergistic agonism was observed 
















of exogeneous 500nM AI-2 (Figure 3.13b; light gray bars).  Surprisingly ester-protected 
analogs caused more synergism that free hexyl-DPD.  Similarly AI-2 prodrugs were also 
tested in the presence of 500nM AI-2 (Figure 3.13a). 
 
Figure 3.14:  Bioluminescence induction in V. harveyi BB170 (LuxS+) in response to various AI-2 pro-
drugs over time 
 
Although ester protected AI-2 derivatives were active they did not cause 
bioluminescence to the degree to which free AI-2 induced (Figure 3.14a) in V. harveyi 
BB170 (LuxS+).  It is possible that these analogs are limited by the time needed for 
cleavage of the ester groups.  As Figure 3.14 shows the activity of ester protected AI-2s 
increased significantly from 3hrs to 6hrs.  This suggests that these analogs may have a 


























Figure 3.15: AI-2 dependent β-galactoside production in E. coli LW7 (LuxS-) in response to 
isobutyl, diaceate isobutyl, hexyl and diacetate hexyl in the presence of AI-2 (1:1 ratio) 
 
Finally ester protected analogs were screen for activity in E. coli.  Since isobutyl-
DPD was identified as the best inhibitor in E. coli, this analog and diacetate isobutyl 
(132c) was compared for antagonism of β-galactosidase production in the presence of 
exogeneous AI-2.  Hexyl-DPD (111) and diacetate hexyl (132b) was also tested.  Results 
showed that the ester protected inhibitors were able to compete with AI-2 as well as the 
free analogs (Figure 3.15).  Similarly diacetate AI-2 (132a) was able to induce β-
galactosidase production although to a lesser extent than AI-2  (Supplementary Figure 
































Figure 3.16: Models of biological activity of ester protected; a) Required entry and exit of ester analogs 
suggests time-dependent activity in V. harveyi; b) Required entry only suggests non-time-dependent 





In conclusion although ester protected AI-2 and analogs have similar bioactivity 
as the free DPDs there seem to be a dependence on time for bioluminescence induction.  
This would be expected since these analogs need to be cleaved before they can obtain the 
active cyclic forms of AI-2 (and presumably analogs).  This time dependence is not 
observed in the case of β-galactosidase production in E. coli.  Figure 3.16 provides 
models of the proposed path of ester protected AI-2 in these two systems.  It has been 
suggested that AI-2 and analogs can traverse cell membranes through passive diffusion. 
Therefore it is plausible that in the case of V. harveyi, ester protected analogs must first 
diffuse into the cell where it can be cleaved by esterases.  Free analogs then must exit and 
cyclize into the active form (S-THMF-borate) to induce bioluminescence by binding 
LuxPQ.  In E. coli ester protected analogs likely have a more direct path to initiating 
activity.  Once inside the cell, ester protected analogs can be cleaved and get directly 
phosphorylated by LsrK.  Since AI-2 binding proteins exist inside the cell in E. coli there 
is no need for the cleaved products to exit and re-enter through LsrB.  Since there are 
several transport pathways in E. coli further studies are need to confirm this model.  
These models suggest that the V. harveyi system is more sensitive to the time required for 










Conclusions, Broader Impact and Future Work 
 
4.1 Conclusion 
 The development of a new synthesis of AI-2 has enabled the construction of a 
large library of analogs with diverse groups at the C1 position.93, 97 Linear, branched, 
cyclic and aromatic analogs of AI-2 have been synthesized which allow for probing into 
the length, bulk and electronic requirements of the C1 position.97, 101 In addition, 
variations at the C4 and C5 positions have been made which also give insight into the 
structural requirements of AI-2 for signaling and stability.  
 Since AI-2 is a universal signaling molecule, access to this library of analogs has 
allowed for the perturbation of AI-2 signaling in several quorum-sensing systems.101 In V. 
harveyi AI-2 analogs of various shapes and sizes all caused synergistic agonism of AI-2 
induced bioluminescence.97 In E. coli, linear analogs with chain lengths of three carbons 
or greater as well as branched analogs were shown to antagonize the lsr based AI-2 
response.101 Ironically in S. typhimurium, which is known to have homologous quorum 
sensing proteins as E. coli, only butyl-DPD (110) and isobutyl-DPD (116) were found to 
be inhibitors. 101 Overall several potent inhibitors were identified many of which are 
active in more than one organism.  Isobutyl-DPD (116) is the most potent inhibitor of 
enteric bacteria while butyl-DPD (110) and cyclopentyl-DPD (121) are also very potent 
inhibitors in E. coli (see Table 4.1).  Additionally in P. aeruginosa, although AI-2 is not 







Table 4.1:  Inhibitor Concentration (IC50) of the most potent C1-inhibitors  
Inhibitory Concentrations (IC50/µM) 
  E. coli 
Standard Error 
(logIC50) S. typhimurium 
Standard Error 
(logIC50) 
Isobutyl-DPD 0.1073 0.1813 40 0.1164 
Butyl-DPD 5.934 0.1927 >40 ND 
Cyclopentyl-DPD 4.885 0.1464 >40 ND 
Heptyl-DPD 31.87 0.244 >40 ND 
Phenyl-DPD >40 ND >40 ND 
 
 
Finally individual AI-2 analogs were found to be both broad- and selective-
inhibitors of mixed culture synthetic ecosystems.101 Also a “cocktail” of analogs 
including isobutyl-DPD (116) and phenyl-DPD (125) were found to simultaneously 
affect diverse organisms in a synthetic ecosystem.  
The versatility of this new synthesis is demonstrated  not only the construction of 
C1 analogs but also C4 and C5 analogs.  Deoxy-analogs lacking the hydroxyl group on 
C5 allowed for investigations into the importance of phosphorylation on inhibition in 
enteric bacteria.  Also ester-protection at both the C4 and C5 position offer the advantage 
of silica purification.   Moreover ester-protected antagonists , isobutyl diacetate (132c) 
and hexyl diacetate (132b), showed the same activity as free analogs in E. coli.  Although 
agonist, methyl diacetate (132a), demonstrate slightly lesser activity.  A slow-releasing 
mechanism involving cell entry and cleavage by the ester analogs has been proposed.  
This may allow sustained modulation of quorum sensing processes in V. harveyi or other 
organism.  Overall the conciseness and versatility of this new synthesis has provided new 





4.2 Broader Impact 
The broader impact of this unique body of work is quite diverse.  In addition to a 
new synthetic route to AI-2, which is amenable to several variations (i.e. C1 alkyl groups, 
C4 and C5 groups), the preliminary biological work presented opens the field for massive 
exploration.  Not only has possible anti-quorum sensing therapeutic targets been 
identified, these findings have illuminated new aspects of the universal nature of AI-2 
(i.e., P. aerugionsa inhibition, cocktail approach in mixed cultures, synergistic agonism). 
The ability of AI-2 to respond to an organism in which it is not produced is an 
interesting phenomenon.83 The flexibility of this new synthesis would allow analogs to be 
designed containing functional groups capable of “tagging” proteins with which it 
intereacts.  Using this strategy, new AI-2 receptor proteins can be identified in organisms 
where the AI-2 signaling pathway is not well understood.   
 Although much research has been done in recent years to better understand how 
AI-2 effects pathogenesis, a detailed understanding only exists in a handful of 
organisms.42, 74 V. harveyi bioluminescence induction is a typical reporter of AI-2 activity 
and synergistic agonism by analogs have wide reaching implications.  Recently it has 
been found that the quorum sensing regulator, LuxR, represses type III secretion in V. 
harveyi in addition to activating bioluminescence.46a Therefore synergistic agonists may 
enhance the suppression of type III secretion in this organism.  Similarly in V. cholerae, 
AI-2 (and CAI-1) activated gene expression results in repression of biofilm formation and 
virulence.51 Thus, synergistic agonists may inhibit pathogenesis in this organism as well.  




have homologues quorum sensing systems as V. harveyi.44a, 60, 97, 111  It remains to be seen 
how C1 analogs will affect quorum sensing controlled processes in these organisms.   
 Additionally the role of AI-2 mediated quorum sensing in biofilm formation is not 
fully understood in many organisms.78  The recent discovery that biofilm architecture in 
E. coli is affected by LsrR (and AI-2), is key to understanding how organisms control 
biofilm.103  Our finding that C1 analogs are processed by AI-2 enzymes in E. coli and 
likely bind LsrR will be useful in understanding what effect altering the C1 position of 
AI-2 has on biofilm formation and architecture in E. coli.  The potential insights obtained 
from these studies could then be extended to understand biofilm formation on a more 
global platform.  
Moreover our finding that AI-2 analogs are effective in a variety of mixed culture 
environments is extremely relevant to oral microbes which often are involved in mixed 
culture biofilm formation.43, 53 The ability of our analogs to either selectively or broadly 
disturb these organisms’ quorum sensing network could be useful in dental care. 
 
4.3 Future Work 
 This research has revealed and defined the structural requirements of AI-2 
signaling pathways.  Although synergistic agonism is observed among all analogs in V. 
harveyi, it is known that the cyclic form of AI-2 is the active form in V. harveyi.  
Therefore synthesis of “locked” cyclic analogs may provide enhanced synergistic effects 
especially if side chains which showed more pronounce effects in this work are 
incorporated.  Likewise in enteric bacteria our in vitro phosphorylation suggested that it 




inhibition among C1 analogs observed in this organism could be due to some analogs 
more readily adapting the linear conformer and thus being more efficiently 
phosphorylated by LsrK than analogs which may prefer to exist in the cyclic conformer.  
Therefore synthetic design of stable, cell permeable-phospho-analogs may be more 
potent inhibitors than the unphosphorylated C1 analogs identified in this work.  Since 
preferred C1 side chains have been found which effect E. coli and S. typhimurium, new 
analogs could be designed to be selective or broad-spectrum based on the side chain 
installed.  
 In addition to structural insights, biological insights have also been gained.  In V. 
harveyi the absence of synergistic agonism in mutant strains strongly suggest that this 
effect is caused by allosteric binding of analogs to LuxPQ.  The complex interactions 
between LuxP and LuxQ have been proven to effect AI-2 sensitivity (see Section 3.1).47a 
However direct binding assays could be problematic since AI-2 most likely has a much 
higher binding affinity for LuxPQ than analogs.  Therefore a fluorescence-based sensor 
may be a more effective method to monitor binding of analogs to LuxPQ. Pei has 
constructed a LuxPQ which contains a fluorophore and quencher at the LuxQ hinge of 
LuxP.117 Therefore monitoring the behavior of this LuxPQ-probe in the presence of   C1 
analogs may be more beneficial since fluorescence is highly sensitive.  Any subtle 
changes which the analogs cause could be detected and analyzed to understand their 
synergistic effect.  Other methods including orthogonal chemical genetics have also been 
used to explore the affect of small molecules on proteins such histidine kinases.118   
 The different responses observed in lsr expression in E. coli and S. typhimurium is 




presence of identical proteins involved in AI-2 processing in both organisms.40  Our C1 
analogs have revealed that subtle variations exists which alter S. typhimurium’s 
susceptibility.  C1 analogs in this manner could be used as actual probes to decipher 
where biological variations originate.  For example E. coli transporter mutants were 
tested and it was found that alternative transport into the cell exists.  This alternative 
pathway may not exist in S. typhimurium therefore testing our C1 inhibitors in a 
transporter mutant strain for this organism could show a difference.  Another possible 
approach would be to compare the substrate specificity of LsrK in the two organisms.  
LsrK of S. typhimurium has been shown to be substrate specific not being able 
phosphorylating glucose or ribose.38 Thus the conclusions made from in vitro 
phosphorylation using E. coli LsrK may not directly coorelate to S. typhimurium.  Finally 
binding assays of C1 analogs using purified LsrR from E. coli and S. typhimurium may 
show that the divergent biological effects of analogs is due to different binding affinities 
for LsrR.  Ultimately the wide variety of C1 analogs available will allow the underlying 
dissimilarities of these enteric bacteria to be unraveled in the future. 
 Additionally the biological relevance of AI-2 internalization and processing in 
enteric bacteria is thought to be a method of quenching the AI-2 signal of other bacteria 
in its niche.40, 106  To prove this theory it is necessary to conduct a more exhaustive study 
of synthetic ecosystems.  A concentration-dependent effect of exogenous AI-2 and 
analogs on the response of an organism in the presence and absence of various other 





The observation that AI-2 and analogs are able to perturb quorum sensing in P. 
aeruginosa is fascinating yet the idea that such effects are due to AI-1 likeness requires 
further investigation. The effect of analogs on other quorum sensing process in P. 
aeruginosa could be tested such as elastase B production. Also screening with mutant 
strains are needed to identify what pathway AI-2 and analogs are acting on to effect 
quorum sensing in P. aeruginosa (i.e., las, rhl, etc.). Additionally analogs should be 
screened in other AI-1 dominate pathways such as V. cholerae to see if similar effects are 
observed.   Once a thorough understanding of AI-2/analogs role in effecting the quorum 
sensing circuitry of these unlikely organism, combination therapies maybe desired which 






Experimental, Supplemental Figures and References 
5.1 General Methods of Synthesis 
Air and moisture sensitive reactions were carried out in oven-dried glasswares 
sealed with rubber septa under a positive pressure of dry argon or nitrogen, unless 
otherwise indicated. Reactions were stirred using Teflon-coated magnetic stir bars.  
Organic solutions were concentrated using a Büchi rotary evaporator with an aspirator 
pump. Dry tetrahydrofuran was obtained using PureSolvent™ prior to use. Dry 
acetonitrile was distilled from CaH2 prior to use.  Thin-layer chromatography (TLC) was 
performed on Merck Kieselgel 60 F254 plates with a 365 nm fluorescent indicator. The 
TLC was visualized by ultraviolet light and acidic p-anisaldehyde stain followed by 
gentle heating.  The crude reaction mixtures were purified by flash chromatography on 
silica gel (230-400 mesh).   
 NMR spectra were measured on Bruker AV-400, Bruker DRX-400 (1H at 400 
MHz, 13C at 100MHz), Bruker DRX-500 (1H at 500 MHz, 13C at 125MHz) or Bruker 
AVIII-600 (1H at 600 MHz, 13C at 150MHz). Data for 1H -NMR spectra are reported as 
follows: chemical shift (ppm, relative to residual solvent peaks or indicated external 
standards; s = singlet, d = doublet, t = triplet, q = quartet, dd = doublet of doublets, td = 
triplet of doublets, m = multiplet), coupling constant (Hz), and integration. Data for 13C -
NMR are reported in terms of chemical shift (ppm) relative to residual solvent peak. 
Mass spectra (MS) and high resolution mass spectra (HRMS) were recorded by JEOL 
AccuTOF-CS (ESI positive, needle voltage 1800~2400 eV). Infrared spectra (IR) were 





 Synthesis of Diazodiols: To a solution of the diazocarbonyl in anhydrous 
acetonitrile (0.2M) was added DBU (0.16-0.20 eq) and the requisite aldehyde (2-(tert-
butyldimethylsilyloxy)) acetaldehyde or acetaldehyde) (1-1.5 eq). The reaction was 
stirred at room temperature under nitrogen for 4-8 hours and monitored by TLC. Upon 
disappearance of starting material, the reaction was quenched with sodium bicarbonate. 
The organic layer was extracted with dichloromethane (3 x 20 mL) and dried with 
magnesium sulfate. The solvent was evaporated under reduced pressure. To a solution of 
crude product in anhydrous tetrahydrofuran (0.2M) TBAF was added (1-2 eq) at 0o C. 
The solution was allowed to warm to room temperature and stirred for 1-3 hours under 
nitrogen. The solvent was evaporated and the crude product was purified by column 
chromatography. The product eluted as yellow oil with 1:3 to 3:2 ethyl acetate:hexane. 
 Synthesis of DPDs: To a solution of diazodiol (1 eq) in acetone (1-2 mL) was 
added dioxirane (15-20 mL) in acetone dropwise. The reaction was allowed to stir at 
room temperature (1-2 hrs) until complete disappearance of starting material as indicated 
by TLC (loss of UV activity). Solvent and excess reagent was evaporated under reduced 
pressure. NMR was taken without further purification. 
Synthesis of Quinoxaline Derivatives: To a solution of DPD-analog was added 
1, 2- phenylenediamine (1.5 eq). The reaction was stirred at room temperature for 10 
minutes and then the reaction mixture was washed with (2M) HCl. The crude mixture 







5.2 Methods of Biological Evaluation 
Bacterial Strains and Growth Condition  
S. typhimurium and E. coli strains were cultured in Luria-Bertani medium (LB, Sigma) at 
either 30C or 37C with vigorous shaking (250 rpm) unless otherwise noted. The V. 
harveyi strains were grown in AB or LM medium. Antibiotics were used for the 
following strains: (60 or 100 µg ml-1) kanamycin for S. typhimurium MET715, (50 µg ml-
1), ampicillin for E. coli LW7 pLW11. (50 µg ml-1) ampicillin and (50 µg ml-1) 
kanamycin for E. coli MDAI-2 pCT6 and E. coli SH3 pLW11 along with (20µg ml-1) 
chloramphenicol for the latter and (20 µg ml-1) kanamycin for V. harveyi BB170. 
 
Modulation of bioluminescence in V. harveyi 
The test compounds were evaluated for their (ant) agonistic activity in V. harveyi 
following reported protocol.  Briefly, V. harveyi strain BB170 or MM32 was grown for 
18 h at 30 °C in AB (or LM) medium and then diluted 1:500 into fresh AB medium. 
Aliquots of analogs (and AI-2) were added to cells in a 96-well plate.  Bioluminescence 
was taken at either 30 min or 1 h intervals.   
 
Measurement of β-galactosidase production in E. coli and S. typhimurium. The QS 
response indicated by lsr gene expression was analyzed in pure culture studies by 
culturing E. coli LW7 pLW11, E. coli ZK126 pLW11 and S. typhimurium MET708, S. 
typhimurium MET715 overnight in LB medium supplemented with appropriate 




antibiotics) and grown to an OD600 of 0.8 - 1.0 at 30 °C, 250 rpm. Cells were then 
collected by centrifugation at 10,000 xg for 10 minutes, and resuspended in 10 mM 
phosphate buffer. AI-2 (40 µM) and the respective analog (40 µM) were added to the E. 
coli or S. typhimurium suspension for 2 hours at 37 °C. AI-2 dependent β-galactosidase 
production was quantified by the Miller assay. 111 
 
Measurement of pyocyanin production.  Pyocyanin was extracted from culture 
supernatants of wild type PAO1, and measured as described by Essar et al.110  Briefly, 2 
mL of chloroform was added to 2 mL of culture supernatant, taken from 19 h cultures 
grown in the presence of DPD analog. After extraction, 1 mL of the chloroform layer was 
transferred to a fresh tube and mixed with 180 µL of 0.2 M HCl. After centrifugation, the 
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Figure S1: β-galactoside production in E. coli LW7 (LuxS-) in response to a) AI-2, b) hexyl-DPD, c) 



















































Figure S4: β-galactoside production in E. coli LW7 and S. typhimurium MET715 (both luxS-) in 






Figure S5: β-galactoside production in E. coli LW9 (LsrB-) in response to a) linear analogs and b) 






































Figure S6:  Pyocanin production in response to a) linear b) branched c) cyclic and d) aromatic C1 

































Figure S7: β-galactoside production in E. coli LW7 and S. typhimurium MET715 (both are LuxS-) 
in response to a) cyclic and b) aromatic analogs 
 
 













































Figure S12: Synergistic agonsism of V. harveyi MM32 (LuxS-) in the prescence of various concentrations 





5.2 NMR Characterizations 
 
 
3-diazo-4, 5-dihydroxypentan-2-one (S1):  1H NMR (400 MHz, CDCl3) δ ppm 4.76 
(1H, m), 3.85 (1H, dd, J = 11.4, 3.2 Hz), 3.75 (1H, dd, J = 11.4, 3.2 Hz), 3.46 (1H, s, br), 
2.69 (1H, s, br), 2.26 (3H, s). 13C NMR (100 MHz, CDCl3) δ ppm 191.7, 66.3, 64.2, 25.6. 










































4-diazo-5,6-dihydroxyhexan-3-one (S2): 1H NMR (400 MHz, CDCl3) δ ppm 4.75 (1H, 
m), 4.48 (1H, br), 4.21 (1H, br), 3.81-3.79 (1H, m), 3.72-3.70 (1H, m), 3.44 (1H, br), 
2.50 (2H, q, J = 7.4 Hz), 1.13 (3H, t, J = 7.4 Hz); 13C NMR (100 MHz, CDCl3) δ ppm 




3-diazo-1,2-dihydroxyheptan-4-one (S3):  1H NMR (400 MHz, CDCl3) δ ppm  4.75 
(1H, m), 4.08 (1H, br), 3.81 (1H, dd, J = 11.2, 3.4 Hz), 3.70 (1H, dd, J = 11.2, 5.4 Hz), 
3.35 (1H, br), 2.45 (2H, t, J = 7.4 Hz), 1.68-1.63 (2H, m), 0.94 (3H, t, J = 7.4 Hz). 13C 
NMR (100 MHz, CDCl3) δ ppm 195.3, 66.6, 64.8, 40.5, 18.6, 14.1.  IR: 3395, 2964, 
2935, 2876, 2082, 1605 cm-1. Yield: 52% (over 2 steps) 
 
 
3-diazo-1,2-dihydroxyoctan-4-one (S4):  1H NMR (400 MHz, CDCl3) 4.75 (1H, br), 
3.83 (1H, dd, J = 3.9, 11.5 Hz), 3.72 (1H, dd, J = 5.3, 11.5 Hz), 3.02 (1H, s, br), 2.45-
2.49 (2H, m), 1.95 (1H, s, br), 1.57-1.65 (2H, m), 1.30-1.40 (2H, m), 0.91 (3H, t, J = 7.3 
Hz) 13C NMR (100 MHz, CDCl3) δ ppm 194.9, 66.2, 64.1, 37.7, 26.5, 22.1, 13.6. IR: 






3-diazo-1,2-dihydroxynonan-4-one (S5): 1H NMR (CDCl3, 400 MHz) δ 4.78 (1H, t, J= 
4.4 Hz), 3.83-3.85 (1H, m), 3.73 (1H, dd, J= 16.8, 5.6 Hz), 2.49 (2H, t, J= 7.6 Hz), 1.65 
(2H, t, J= 7.2 Hz), 1.32-1.33 (4H, m), 0.89-0.93 (3H, m); 13C NMR (CDCl3, 100 MHz) δ 
195.9, 96.3, 67.1, 64.9, 39.1, 31.9, 24.9, 23.1, 14.5. IR: 3377, 2957, 2931, 2872, 2085, 
1710, 1609 cm-1 Yield: 25% (over 2 steps) 
 
 
 3-diazo-1,2-dihydroxydecan-4-one (S6): 1H NMR (CDCl3, 400 MHz) δ 4.75 (1H, br), 
3.77-3.79 (1H, m), 3.68 (1H, dd, J= 13.6, 4.8 Hz), 2.47 (2H, t, J= 6.4, 5.6 Hz), 1.58-1.64 
(2H, m), 1.26-1.35 (6H, m), 0.87-0.91 (3H, m); 13C NMR (CDCl3, 100 MHz) δ 195.2, 
70.5, 65.9, 64.5, 38.5, 31.7, 29.0, 24.8, 22.6, 14.2. IR: 3394, 2956, 2928, 2959, 2086, 
1610 cm-1 Yield: 49% (over 2 steps) 
 
 
3-diazo-1,2-dihydroxyundecan-4-one (S7): 1H NMR (CDCl3, 400 MHz) δ 4.78 (1H, 
br), 3.86-3.89 (1H, m), 3.77 (1H, dd, J= 15.2, 4.4 Hz), 3.54 (1H, br), 2.77 (1H, br), 2.50 
(2H, t, J= 7.6 Hz), 1.66 (2H, q, J= 7.2 Hz), 1.27-1.32 (8H, m), 0.91 (3H, t, J= 6.8, 7.2 
Hz); 13C NMR (CDCl3, 100 MHz) δ 195.8, 67.1, 64.8, 38.7, 32.0, 29.6, 29.4, 25.0, 23.0, 






4-diazo-5,6-dihydroxy-2-methylhexan-3-one (S8):  1H NMR (400 MHz, CDCl3) δ ppm 
4.74-4.76 (1H, m), 3.81 (1H, dd, J = 11.5, 3.9 Hz), 3.70 (1H, dd, J = 11.5, 5.6 Hz), 2.79-
2.86 (1H, m), 1.12 (6H, d, J = 6.8 Hz). 13C NMR (100 MHz, CDCl3) δ ppm 199.5, 66.7, 




4-diazo-5,6-dihydroxy-2,2-dimethylhexan-3-one (S9):  1H NMR (400 MHz, CDCl3) δ 
ppm 4.78 (1H, t, J = 4.9 Hz), 3.83 (1H, dd, J = 4.2, 11.5 Hz), 3.74-3.70 (1H, m), 1.23 
(9H, s). 13C NMR (100 MHz, CDCl3) δ ppm 200.6, 67.8, 64.0, 44.3, 26.6. IR:  3358, 
2971, 2361, 2338, 2077, 1702, 1602 cm-1.  Yield: 20% (over 2 steps) 
 
 
 3-diazo-1,2-dihydroxy-6-methylheptan-4-one (S10): 1H NMR (CDCl3, 400 MHz) δ 
4.79 (1H, br), 4.18 (1H, br), 3.83 (1H, dd, J= 11.2, 3.6 Hz), 3.72 (1H, dd, J= 11.6, 5.6 
Hz), 2.36 (2H, d, J= 6.8 Hz), 2.12-2.19 (1H, m), 0.97 (6h, d, J= 6.8 Hz); 13C NMR 
(CDCl3, 100 MHz) δ 195.1, 71.3, 66.6, 64.8, 47.5, 26.3, 22.9. IR: 3377, 2960, 2873, 






3-diazo-1,2-dihydroxy-5-methylheptan-4-one (S11): 1H (CDCl3, 400MHz) δ 4.80 (1H, 
br), 3.83 (1H, dd, J= 15.6, 4.4 Hz), 3.73 (1H, dd, J= 16.4, 4.8 Hz), 2.65-2.70 (1H, m), 
1.69-1.77 (1H, m), 1.44-1.51 (1H, m), 1.14-1.16 (3H, d, J= 6.8 Hz), 0.92-0.96 (3H, m); 
13C (CDCl3, 100 MHz) δ 199.5, 67.2, 64.8, 43.6, 27.3, 17.1, 12.3. IR: 3405, 2967, 2935, 
2878, 2084, 1755, 1605 cm-1 Yield: 54% (over 2 steps) 
 
 
3-diazo-1,2-dihydroxy-6,6-dimethylheptan-4-one (S12): 1H NMR (CDCl3, 400 MHz) δ 
4..77--4..79 ( (m, 1H), 3.82-3.85 (m, 1H), 3.72-3.75 (m, 1H) 2.36 (s, 2H), 1.05 (s, 9H); 
13C NMR (CDCl3, 100 MHz) 194.8, 71.8, 66.9, 64.7, 50.9, 32.9, 30.0.IR: 3387, 2955, 
2870, 2082, 1602, 1467cm-1 Yield: 53% (over 2 steps) 
 
 
1-cyclopropyl-2-diazo-3,4-dihydroxybutan-1-one (S13):  1H NMR (400 MHz, CDCl3) 
δ ppm 4.81 (1H, s, br), 3.87-3.92 (1H, m), 3.79-3.83 (1H, m), 3.38 (1H, s, br), 2.62 (1H, 
s, br), 1.94-2.01 (1H, m), 1.13-1.17 (2H, m), 0.92-0.97 (2H, m); 13C NMR (100 MHz, 
CDCl3) δ ppm 193.5, 66.4, 63.7, 16.4, 9.5. IR: 3401, 2929, 2362, 2088, 1690, 1612 cm-1. 






1-cyclobutyl-2-diazo-3,4-dihydroxybutan-1-one (S14): H1 (CDCl3, 400MHz) ppm δ 
4.75 (1H, br), 3.72-3.83 (2H, m), 2.32-2.34 (2H, m), 2.16-2.17 (2H, m), 1.97-2.00 (2H, 
m), 1.86-1.91 (2H, m); C13 (CDCl3, 100MHz) ppm δ 196.9, 67.0, 64.7, 42.5, 24.9, 18.3 
IR: 3376, 2944, 2867, 2085, 1754, 1697, 1603 cm-1. Yield: 21% (over 2 steps) 
 
 
1-cyclopentyl-2-diazo-3,4-dihydroxybutan-1-one (S15) : 1H NMR (400 MHz, 
CDCl3) δ ppm 4.75-4.77 (1H, m), 4.21 (1H, br), 3.77-3.81 (1H, m), 3.67-3.71 (1H, m), 
3.50 (1H, br), 1.77-1.80 (4H, m), 1.86-1.89 (2H, m), 1.55-1.59 (2H, m) 13C NMR (100 
MHz, CDCl3) δ ppm 198.4, 66.6, 64.9, 47.0, 29.8, 26.4 IR 3376, 2952, 2869, 2360, 2082, 
1607 cm-1 Yield: 19% (over 2 steps) 
 
 
1-cyclohexyl-2-diazo-3,4-dihydroxybutan-1-one (S16): 1H NMR (400 MHz, CDCl3) δ 
ppm 4.75 (1H, t, J = 4.6, 4.6 Hz), 3.85 (1H, dd, J = 4.1, 11.5 Hz), 3.75 (1H, dd, J = 4.9, 
11.5 Hz), 3.41 (1H, s, br), 2.58 (1H, s, br), 2.49-2.56 (1H, m), 1.74-1.83 (3H, m), 1.68-
1.70 (1H, m), 1.42-1.51 (2H, m), 1.22-1.32 (3H, m). 13C NMR (100 MHz, CDCl3) δ ppm 
198.4, 66.7, 64.3, 46.3, 28.8, 25.5. IR: 3399, 2975, 2932, 2362, 2085, 1616 cm-1. Yield: 






1-cyclohexyl-3-diazo-4,5-dihydroxypentan-2-one (S17):  H1 (400MHz, CDCl3) ppm 
δ:  4.77 (1Η, br s), 3.87-3.84 (1H, m), 3.75 (1H, dd, J= 10.8, 6.8 Hz), 2.35 (2H, d, J= 7.2 
Hz), 1.66-1.79 (6H, m), 1.22-1.33 (4H, m), 0.99-1.05 (2H, m); C13 (100MHz, CDCl3) 
ppm δ:  195.8, 97.1, 64.7, 46.3, 35.6, 33.5, 26.4  
 
 
1-cycloheptyl-2-diazo-3,4-dihydroxybutan-1-one (S18):  1H NMR (400 MHz, CDCl3) 
δ ppm 4.75-4.78 (1H, m), 3.82-3.89 (1H, m), 3.72-3.79 (1H, m), 2.90-2.97 (1H, br), 2.67-
2.75 (1H, m), 1.76-1.89 (5H, m), 1.63-1.72 (2H, m), 1.56-1.61 (4H, m), 1.43-1.51 (2H, 
m); 13C NMR (100 MHz, CDCl3) δ ppm 200.0, 66.9, 64.5, 48.1, 31.0, 28.6, 27.0; IR:  
3401, 2924, 2857, 2086, 1615 cm-1 
 
 
2-diazo-1-(furan-2-yl)-3,4-dihydroxybutan-1-one (S19):  1H NMR (400 MHz, CDCl3) 
δ ppm 7.50 (1H, dd, J=0.7, 1.7 Hz), 7.17 (1H, d, J= 0.7 Hz), 6.55 (1H, dd, J= 1.7, 3.6 
Hz), 4.96 (1H, br), 3.95-3.91 (1H, m), 3.86-3.81 (1H, m), 3.58-3.55 (1H, m) 13C NMR 
(400 MHz, CDCl3) δ ppm 174.3, 151.3, 144.2, 118.0, 111.9, 66.9, 63.8  IR:  3246, 2359, 






2-diazo-3,4-dihydroxy-1-phenylbutan-1-one (S20):  1H NMR (400 MHz, CDCl3) δ 
ppm 7.63-7.65 (2H, m), 7.54-7.56 (2H, m), 7.47-7.50 (1H, m), 4.97 (1H, br), 3.98-4.01 
(2H, m); 13C NMR (400 MHz, CDCl3) δ ppm 190. 3, 137.4, 132.5, 129.2, 127.7, 127.6, 
67.8, 64.7 IR: 3400, 2925, 2360, 2341, 1597, 1570 cm-1 Yield: 18% (over 2 steps) 
 
 
2-diazo-3,4-dihydroxy-1-(4-methoxyphenyl)butan-1-one (S21): 1H NMR (400 MHz, 
CDCl3) δ ppm 7.61-7.62 (2H, m), 6.92-6.96 (2H, m), 4.93 (1H, t, J= 4.8, 4.8 Hz), 3.96 
(1H, dd, J= 4.4, 11.6 Hz), 3.88 (3H, s), 3.85-3.89 (1H, m); 13C NMR (400 MHz, CDCl3) 




2-diazo-1-(4-fluorophenyl)-3,4-dihydroxybutan-1-one (S22): 1H NMR (400 MHz, 
CDCl3) δ ppm 7.61-7.64 (2H, m), 7.13-7.16 (2H, m), 4.93 (1H, t, J= 4.8, 4.4 Hz), 3.96 
(1H, dd, J=4.4, 7.2 Hz), 3.87 (1H, dd, J= 4.8, 11.2 Hz) 13C NMR (400 MHz, CDCl3) δ 






2-diazo-3,4-dihydroxy-1-(4-nitrophenyl)butan-1-one (S23):  H1 (400MHz, d6-
Acetone) ppm δ 8.37−8.40 (2Η, m), 7.94-7.96 (2H, m), 4.85 (1H, br s), 3.81 (2H, d, 
J=4.8 Hz); C13 (100MHz, d6-Acetone) ppm 
δ:  149.7, 128.9, 124.2, 78.7, 66.6, 64.5; Yield: 16% (over 2 steps) 
 
  
3-diazo-4-hydroxypentan-2-one (S24): 1H NMR (CDCl3, 400 MHz) δ 5.04 (d, J= 5.6 
Hz, 1H), 3.22 (br, 1H), 2.28 (s, 3H), 1.77 (br, 1H), 1.40 (d, J= 6.4 Hz, 3H); 13C NMR 
(CDCl3, 100 MHz) δ 192.3, 62.4, 26.2, 19.5. IR: 3391, 2922, 2850, 2480, 2363, 2093, 





3-diazo-2-hydroxy-6-methylheptan-4-one (S25):  1H NMR (CDCl3, 400 MHz) δ ppm 
5.02 (d, J= 6.0 Hz, 1H), 3.53 (br, 1H), 2.35 (d, J= 7.2 Hz, 2H), 2.12-2.19 (m, 1H), 1.38 
(d, J= 6.4 Hz, 3H), 0.95 (d, J= 6.8 Hz, 6H); 13C NMR (CDCl3, 100 MHz) δ ppm 195.1, 
72.9, 62.3, 47.6, 37.0, 26.2, 22.9, 19.6. IR: 3401, 2960, 2872, 2075, 1609 cm-1 Yield: 






1-cyclohexyl-2-diazo-3-hydroxybutan-1-one (S26): 1H NMR (CDCl3, 400 MHz) δ ppm 
5.04 (1H, q, J= 6.4, 6.8, 6.4 Hz), 2.52-2.56 (1H, m), 1.76-1.79 (4H, m), 1.69-1.73 (2H, 
m), 1.39-1.54 (2H, m), 1.33 (3H, d, J= 5.2 Hz), 1.22-1.28 (2H, m); 13C NMR (CDCl3, 
100 MHz) δ ppm 198.9, 62.4, 46.7, 29.1, 26.2, 21.7, 19.6, 14.6. IR: 2931, 2856, 2361, 
2340, 2076, 1616 cm-1 
 
 
DPD (4,5-dihydroxypentane-2,3-dione) and cyclic compounds (55):  1H NMR (400 
MHz, D2O) δ ppm 4.24-4.28 (2H,m), 4.04-4.10 (6H, m), 3.93-3.95 (2H, m), 3.84-3.86 
(2H, m), 3.67-3.72 (4H, m), 3.52-3.59 (3H, m), 3.44-3.48 (2H, m), 2.26 (3H, s), 1.30 (6H, 
s), 1.26 (6H, s). 13C NMR (100 MHz, D2O) δ ppm 103.9, 99.1, 74.3, 73.5, 71.2, 61.4, 
24.8, 20.2, 19.6. 
 
 
Ethyl-DPD (1,2-dihydroxyhexane-3,4-dione) and cyclic compounds (108): 1H NMR 
(400 MHz, CDCl3) δ ppm 4.94 (1H, t, J = 3.1), 3.99-4.07 (2H, m), 2.91-3.01 (1H, m), 
2.75-2.85 (1H, m), 1.80-1.88 (2H, m), 1.15 (3H, t, J = 7.2 Hz). 13C NMR (100 MHz, 
CDCl3) δ ppm 200.2, 198.8, 75.2, 64.2, 30.9, 18.9, 6.9.  
 
 
Propyl-DPD (1,2-dihydroxyheptane-3,4-dione) and cyclic compounds (109): 1H 




(1H, m), 2.70-2.78 (1H, m), 1.61-1.70 (3H, m), 0.88-0.99 (6H, m). 13C NMR (100 MHz, 
CDCl3) δ 199.3, 198.4, 74.7, 63.7, 38.7, 16.2, 13.5. 
 
 
Butyl-DPD (1,2-dihydroxyoctane-3,4-dione) and cyclic compounds (110):  1H NMR 
(400 MHz, CDCl3) δ ppm 4.94, (1H, t, J = 3.2 Hz), 3.98-4.06 (2H, m), 2.86-2.94 (1H, m), 
2.74-2.83 (1H, m), 1.59-1.67 (2H, m), 1.34-1.43 (2H, m), 0.95 (3H, t, J = 7.3 Hz).  13C 





Pentyl-DPD (1,2-dihydroxynonane-3,4-dione) and cyclic compounds (111): 1H NMR 
(D2O, 400 MHz) a: δ 3.85-3.87 (1H, m), 3.60-3.64 (1H, m), 3.48-3.43 (1H, m), 2.62-2.67 
(2H, m), 1.51-1.61 (2H, m), 1.13-1.17 (2H, m), 0.70-0.73 (3H, m); b: δ 3.97-4.01 (1H, 
m), 3.73-3.80 (1H, m), 3.60-3.64 (1H, m), 1.40-1.43 (2H, m), 1.13-1.17 (6H, m), 0.70-
0.73 (3H, m); c: δ 3.75-3.80 (1H, m), 3.38-3.48 (1H, m), 3.34-3.38 (1H, m), 1.40-1.43 
(2H, m), 1.13-1.17 (6H, m), 0.70-0.73 (3H, m); 13C NMR (CDCl3, 125 MHz) δ 212.9, 






Hexyl-DPD (1,2-dihydroxydecane-3,4-dione) and cyclic compounds (112): 1H NMR 
(D2O, 600 MHz) a: δ 4.01-4.05 (1H, m), 3.64-3.68 (1H, m), 3.48-3.52 (1H, m), 2.59-2.70 
(2H, m), 1.57-1.62 (2H, m), 1.16-1.18 (6H, m) 0.74-0.75 (3H, m); b: δ 4.25-4.27 (1H, 
m), 3.82-3.84 (1H, m), 3.64-3.68 (1H, m), 1.43-1.46 (2H, m), 1.16-1.18 (8H, m), 0.74-
0.75 (3H, m); c: δ 3.91-3.92 (1H, m), 3.48-3.52 (1H, m), 3.39-3.42 (1H, m), 1.43-1.46 
(2H, m), 1.16-1.18 (8H, m), 0.74-0.75 (3H, m); 13C NMR (CDCl3, 150 MHz) δ 73.7, 





Heptyl-DPD (1,2-dihydroxyundecane-3,4-dione) and cyclic compounds (113): 1H 
NMR (D2O, 400 MHz) a: δ 4.04-4.05 (1H, m), 3.65-3.71 (1H, m), 3.49-3.54 (1H, m), 
2.64-2.69 (2H, m), 1.58-1.63 (2H, m), 1.18-1.20 (8H, m), 0.74-0.76 (3H, m); b: δ 4.25-
4.27 (1H, m), 3.83-3.86 (1H, m), 3.65-3.71 (1H, m), 1.46-1.48 (2H, m), 1.18-1.20 (8H, 
m), 0.74-0.76 (3H, m); c: δ 3.91-3.94 (1H, m), 3.49-3.54 (1H, m), 3.40-3.44 (1H, m), 
1.46-1.48 (2H, m), 1.18-1.20 (8H, m), 0.74-0.76 (3H, m); 13C NMR (CDCl3, 125 MHz) δ 






Isopropyl-DPD (1,2-dihydroxy-5-methylhexane-3,4-dione) and cyclic compounds 
(114): 1H NMR (400 MHz, CDCl3) δ ppm 4.92 (1H, t, J = 3.2 Hz), 3.98 (2H, d, J = 3.3 
Hz), 3.72 (1H, q, J = 7.0 Hz), 3.34-3.41 (1H, m), 1.23-1.29 (3H, m), 1.19 (1H, dd, J = 
6.9, 1.4 Hz) 1.15 (6H, dd, J = 6.9, 6.3 Hz), 1.03 (3H, dd, J = 6.9, 1.5 Hz), 0.92 (1H, d, J = 
6.9 Hz); 13C NMR (100 MHz, CDCl3) δ ppm 203.1, 199.5, 75.3, 63.9, 35.3, 34.1, 30.1, 
17.7, 17.3.  
 
 
Tertbutyl-DPD (1,2-dihydroxy-5,5-dimethylhexane-3,4-dione) and cyclic compounds 
(115): 1H NMR (400 MHz, CDCl3) δ ppm 4.78 (1H, t, J = 3.5 Hz), 4.37-4.45 (2H, m), 
3.91 (2H, d, J = 3.5 Hz), 3.69-3.74 (1H, m), 1.27 (9H, s), 1.23 (3H, s), 1.09 (1H, s), 1.06 
(1H, s), 1.01 (6H, s).  13C NMR (100 MHz, CDCl3) δ ppm 213.8, 207.4, 201.4, 101.7, 
75.5, 73.1, 66.8, 63.2, 42.9, 37.1, 26.6, 26.1, 24.6, 24.1. 
 
 
Isobutyl-DPD (1,2-dihydroxy-6-methylheptane-3,4-dione) (116):  1H NMR (D2O, 400 
MHz) δ 3.85 (1H, dd, J=11.2, 3.6 Hz), 3.68 (1H, dd, J= 15.6, 3.6 Hz), 3.52 (1H, dd, J= 
19.2, 7.6 Hz), 2.54-2.59 (2H, m), 1.97-2.02 (1H, m), 0.83-085 (6H, m); 13C NMR 






Secbutyl-DPD (1,2-dihydroxy-5-methylheptane-3,4-dione) and cyclic compounds 
(117): 1H NMR (D2O, 400 MHz) a: δ 3.63-3.66 (1H, m), 3.46-3.51 (1H, m), 2.95-2.98 
(1H, m), 1.46-1.58 (2H, m), 0.79-0.84 (3H, m), 0.68-0.77 (3H, m); b: δ 3.81-3.83 (1H, 
m), 3.70-3.74 (1H, m), 1.46-1.58 (2H, m), 1.19-1.28 (1H, m), 0.89-0.94 (3H, m), 0.68-
0.77 (3H, m); c: δ 3.81-3.83 (1H, m), 3.70-3.74 (1H, m), 1.46-1.58 (2H, m), 1.19-1.28 
(1H, m), 0.89-0.94 (3H, m), 0.68-0.77 (3H, m); 13C NMR (CDCl3, 125 MHz) δ 217.2, 
97.8, 75.2, 74.2, 72.4, 63.5, 62.3, 42.1, 40.9, 27.3, 26.9, 25.4, 24.2, 17.3, 16.9, 14.8, 12.1, 





Neopentyl-DPD (1,2-dihydroxy-6,6-dimethylheptane-3,4-dione) (118): 1H NMR 
(D2O, 400 MHz) δ 3.81-3.85 (1H, m), 3.65-3.69 (1H, m), 3.48-3.53 (1H, m), 2.60 (2H, 
dd, J= 44.0, 13.2 Hz), 0.91 (9H, s); 13C NMR (CDCl3, 100 MHz) δ 210.8, 202.1, 96.8, 
74.3, 74.0, 63.2, 51.7, 48.3, 48.2, 31.2, 30.1, 29.3, 29.1. 
 
 
Cyclopropyl-DPD (1-cyclopropyl-3,4-dihydroxybutane-1,2-dione) and cyclic 




(2H, d, J =3.2 Hz), 2.71-2.75 (1H, m), 1.09-1.24 (12H, m), 0.83-0.89 (4H, m).13C NMR 
(100 MHz, CDCl3) δ ppm 74.7, 63.7, 29.7, 16.3, 14.3. 
 
 
Cyclobutyl-DPD (1-cyclobutyl-3,4-dihydroxybutane-1,2-dione) and cyclic 
compounds (120): 1H NMR (400 MHz, D2O) δ ppm 4.78-4.81 (1H, m), 4.51-4.61 (1H, 
m), 4.39-4.42 (1H, m), 4.20-4.29 (2H, m), 4.11-4.16 (1H, m), 4.00-4.06 (1H, m), 3.87-
3.90 (1H, m), 3.75-3.79 (2H, m), 3.61-3.69 (2H, m), 3.42-3.49 (1H, m), 2.56-2.78 (2H, 
m), 2.81-2.89 (1H, m), 2.43-2.55 (2H, m), 1.97-2.13 (18H, m), 1.72-1.96 (24H, m); 13C 
NMR (100 MHz, D2O) 104.6, 75.5, 73.9, 71.7, 70.9, 69.4, 61.4, 54.2, 38.1, 30.6, 25.6, 
25.5, 25.4, 23.0, 22.9, 22.5, 18.2, 17.8 
 
 
Cyclopentyl-DPD (1-cyclopentyl-3,4-dihydroxybutane-1,2-dione) and cyclic 
compounds (121):  1H NMR (400 MHz, D2O) δ ppm 4.03-4.06 (1H, m), 3.88-3.90 (1H, 
m), 3.77-3.81 (1H, m), 3.65-3.69 (1H, m), 3.49-3.54 (1H, m), 3.31-3.35 (1H, m), 2.17-
2.26 (1H, m), 1.80-1.83 (2H, m), 1.39-1.67 (18H, m); 13C NMR (100 MHz, D2O) 218.1, 






Cyclohexyl-DPD (1-cyclohexyl-3,4-dihydroxybutane-1,2-dione) and cyclic 
compounds (122): 1H NMR (400 MHz, CDCl3) δ ppm 4.93 (1H, br), 4.00 (2H, d, J = 2.8 
Hz), 3.14-3.20 (1H, m), 1.71-1.92 (18 H, m), 1.23-1.48 (16H, m). 13C NMR (100 MHz, 
CDCl3) δ ppm 202.4, 199.6, 75.2, 63.9, 44.6, 28.1, 27.6, 26.1, 26.0, 25.9, 25.5.  
 
 
Cycloheptyl-DPD (1-cycloheptyl-3,4-dihydroxybutane-1,2-dione) (123): 1H NMR 
(400 MHz, D2O) δ ppm 3.78-3.82 (1H, m), 3.73-3.75 (1H, m), 3.64-3.66 (1H, m), 3.61-





CH2-Cyclohexyl-DPD (1-cyclohexyl-4,5-dihydroxypentane-2,3-dione) (124): 1H NMR 
(400 MHz, D2O) δ ppm 3.65-3.69 (2H, m), 2.60-2.62 (1H, m), 1.79-1.83 (2H, m), 1.54-
1.60 (3H, m), 1.04-1.23 (6H, m), 0.82-0.94 (4H, m) 13C NMR (100 MHz, D2O) 199.5, 
198.3, 75.2, 64.1, 44.7, 35.2, 33.6, 33.5, 33.4, 26.5, 26.4, 26.3 
 
 
Phenyl-DPD (3,4-dihydroxy-1-phenylbutane-1,2-dione) (125): 1H NMR (400 MHz, 




7.32-7.34 (9H, m), 4.93-4.95 (1H, m), 4.46-4.49 (2H, m), 4.30-4.34 (3H, m), 4.23-4.27 
(3H, m), 4.08-4.09 (1H, m), 3.98-4.00 (4H, m), 3.89-3.95 (4H, m), 3.66-3.74 (4H, m) 13C 
NMR (100 MHz, D2O) 137.8, 130.4, 129.6, 129.4, 129.1, 128.5, 128.4, 127.7, 127.4, 
127.3, 100.5, 74.6, 73.7, 71.8, 69.1 
 
 
Furanoyl-DPD (1-(furan-2-yl)-3,4-dihydroxybutane-1,2-dione) (126):  1H NMR (400 
MHz, D2O) δ ppm 7.80 (1H, d, J= 0.5), 7.65 (1H, dd, J= 0.5, 3.7 Hz), 6.64 (1H, dd, J= 
1.7, 3.7 Hz), 4.01 (1H, dd, J= 3.7, 7.6 Hz), 3.73 (1H, dd, J= 3.7, 11.8 Hz), 3.53 (1H, dd, 
J= 7.6, 11.8 Hz), 2.59-2.56 (1H, m); 13C NMR (100 MHz, D2O) 187.9, 149.9, 149.4, 




Fluorophenyl-DPD (1-(4-fluorophenyl)-3,4-dihydroxybutane-1,2-dione) (128): 1H 
NMR (400 MHz, D2O) δ ppm 8.13-8.16 (1H, m) 7.91-7.94 (2H, m), 7.70-7.74 (2H, m), 
7.42-7.46 (4H, m), 7.13-7.19 (6H, m), 7.00-7.08 (4H, m), 4.55-4.58 (1H, m), 4.42-4.46 
(1H, m), 4.27-4.30 (1H, m), 4.19-4.24 (1H, m), 4.00-4.03 (1H, m), 3.95-3.07 (1H, m), 






Nitrophenyl-DPD (3,4-Dihydroxy-1-(4-nitro-phenyl)-butane-1,2-dione) (129): 1H 
NMR (D2O, 400 MHz) 8.17 (2H, dd, J= 0.8, 8.4 Hz), 7.68 (2H, dd, J= 2, 6.8 Hz), 4.47 
(1H, t, J= 6.8, 7.2 Hz), 4.34-4.38 (1H, m), 4.25-4.28 (1H, m), 4.00-4.02 (1H, m), 3.95-
3.98 (1H, m)  
 
 
Deoxy-Methyl DPD (4-hydroxypentane-2,3-dione) (134a): 1H NMR (D2O, 400 MHz) 
δ 3.94 (1H, q, J= 6.5 Hz), 2.25 (3H, s), 1.08 (3H, d, J= 10.0 Hz); 13C NMR (CDCl3, 150 
MHz) δ 211.3, 97.7, 69.8, 24.8, 15.4. 
 
 
 Deoxy-Isobutyl DPD (134b): 1H NMR (D2O, 400 MHz) b: δ 4.23 (1H, q, J= 6.8, 6.8, 
6.8 Hz), 2.82-2.86 (2H, m), 2.28 (2H, s), 1.36-1.38 (3H, m), 1.07-1.11 (6H, m); c: δ 3.84 
(1H, q, J= 6.8, 6.8, 6.8 Hz), 2.76 (2H, d, J= 6.8 Hz), 2.41 (2H, s), 1.36-1.38 (3H, m), 
1.07-1.11 (6H, m) 13C NMR (CDCl3, 125 MHz) δ 217.2, 97.8, 75.2, 74.2, 72.4, 63.5, 
62.3, 42.1, 40.9, 27.3, 26.9, 25.4, 24.2, 17.3, 16.9, 14.8, 12.1, 11.6, 11.3.   
 
 
1-(3-methylquinoxalin-2-yl)ethane-1,2-diol (S27):  1H NMR (500 MHz, CDCl3) δ ppm 




4.03-4.08 (1H, m), 3.86 (1H, dd, J = 11.4, 5.5 Hz), 2.83 (3H, s). 13C NMR (125 MHz, 
CDCl3) δ ppm 153.1, 152.2, 142.1, 139.6, 130.3, 129.8, 128.8, 128.6, 71.2, 66.2, 29.9, 
22.2. HRMS (ESI+): Found 205.0978 Calc’d 205.0977 (M+H). 
 
 
1-(3-ethylquinoxalin-2-yl)ethane-1,2-diol (S28): 1H NMR (500 MHz, CDCl3) δ ppm 
8.10 (1H, dd, J = 8.4, 1.8 Hz), 8.02 (1H, d, J = 8.0 Hz), 7.71-7.78 (2H, m), 5.17 (1H, s, 
br), 4.56 (1H, d, J = 7.0 Hz), 4.01-4.06 (1H, m), 3.83 (1H, dd, J = 11.6, 5.7 Hz), 3.02-
3.16 (2H, m),1.46 (3H, t, J = 7.5 Hz). 13C NMR (125 MHz, CDCl3) δ ppm 156.4, 152.7, 
142.3, 139.5, 130.2, 129.7, 128.9, 128.6, 70.9, 66.7, 29.6, 12.8.  HRMS (ESI+): Found 
219.1131 Calc’d 219.1134 (M+H). 
 
 
1-(3-propylquinoxalin-2-yl)ethane-1,2-diol (S29): 1H NMR (500 MHz, CDCl3) δ ppm 
8.06 (1H, dd, J = 8.3, 1.7 Hz), 8.02 (1H, d, J = 8.0 Hz), 7.70-7.77 (2H, m), 5.17 (1H, s, 
br), 4.56 (1H, d, J = 7.0Hz), 4.06-4.01 (1H, m), 3.83 (1H, dd, J = 11.7, 5.7 Hz), 3.02-3.16 
(2H, m),1.46 (3H, t, J = 7.5Hz). 13C NMR (125 MHz, CDCl3) δ ppm 156.4, 152.7, 142.3, 
139.5, 130.2, 129.7, 128.9, 128.6, 70.9, 66.7, 29.6, 12.8.  HRMS (ESI+): Found 233.1331 






1-(3-butylquinoxalin-2-yl)ethane-1,2-diol (S30): 1H NMR (500 MHz, CDCl3) δ ppm 
8.07 (1H, d, J = 8.0 Hz), 8.03 (1H, d, J = 7.5 Hz), 7.71-7.77 (2H, m), 5.17 (1H, s, br), 
4.57 (1H, s, br), 4.04 (1H, dd, J = 11.6, 3.2 Hz), 3.81 (1H, dd, J = 11.6, 5.9 Hz), 2.99-
3.10 (2H, m), 1.79-1.94 (2H, m), 1.47-1.55 (2H, m), 1.00 (3H, t, J =  7.4 Hz).  13C NMR 
(125 MHz, CDCl3) δ ppm 155.8, 152.8, 142.3, 139.4, 130.2, 129.7, 128.9, 128.6, 70.9, 




1-(3-pentylquinoxalin-2-yl) ethane-1,2-diol (S31): 1H NMR (500 MHz, CDCl3) δ 8.02-
8.08 (2H, m), 7.72-7.76 (2H, m), 5.16-5.18 (1H, m), 4.02-4.05 (1H, m) 3.80-3.83 (1H, 
m), 3.01-3.06 (2H, m), 1.87-1.91 (2H, m), 1.44-1.46 (6H, m), 0.94 (3H, t, J= 7.0, 7.0 Hz); 
13C NMR (125 MHz, CDCl3) δ 155.8, 152.8, 142.3, 139.4, 130.2, 129.7, 128.9, 128.6, 
70.9, 66.8, 34.5, 32.1, 299, 28.7, 22.8, 14.2. HRMS (m/z): Found, 261.1612 Calc’d. 
261.1603 (M+H).  
 
 
1-(3-hexylquinoxalin-2-yl) ethane-1,2-diol (S32):  1H NMR (600 MHz, CDCl3) δ 8.03-
8.08 (2H, m), 7.73-7.77 (2H, m), 5.17 (1H, br), 4.56-4.57 (1H, m), 3.06 (1H, br), 3.81 




0.90-0.92 (3H, m); 13C NMR (150 MHz, CDCl3) δ 155.8, 152.8, 142.3, 139.5, 130.2, 
129.7, 128.9, 128.6, 70.9, 66.8, 34.6, 31.9, 29.6, 29.0, 22.8, 14.3. HRMS (m/z): Found, 
275.1753 Calc’d. 275.1760 (M+H). 
 
 
1-(3-heptylquinoxalin-2-yl) ethane-1,2-diol (S33): 1H NMR (500 MHz, CDCl3) δ 8.02-
8.08 (2H, m), 7.72-7.76 (2H, m), 5.14 (1H, br), 4.55 (1H, br), 4.02-4.07 (1H, m), 3.79-
3.82 (1H, m), 3.01-3.06 (2H, m), 1.87-1.89 (2H, m), 1.46-1.49 (2H, m), 1.30-1.32 (4H, 
m), 0.90 (3H, t, J= 7.0 Hz); 13C NMR (125 MHz, CDCl3) δ 155.8, 152.8, 142.2, 139.4, 
130.2, 129.7, 128.9, 128.6, 70.9, 66.8, 34.6, 31.9, 29.9, 29.4, 29.1, 22.8, 14.3. HRMS 
(m/z): Found, 289.1908 Calc’d. 289.1916 (M+H). 
 
 
1-(3-isopropylquinoxalin-2-yl)ethane-1,2-diol (S34): 1H NMR (600 MHz, CDCl3) δ 
ppm 8.08 (1H, d, J = 7.8 Hz), 8.03 (1H, d, J = 7.8 Hz), 7.71-7.77 (2H, m), 5.22 (1H, s), 
4.69 (1H, s), 4.03 (1H, dd, J = 11.4, 2.5 Hz), 3.77 (1H, dd, J = 11.6, 6.0 Hz), 3.43-3.47 
(1H, m), 1.45 (3H, d, J = 6.7Hz), 1.39 (3H, d, J = 6.7 Hz). 13C NMR (150 MHz, CDCl3) 
δ ppm 160.4, 151.9, 142.5, 139.4, 130.0, 129.7, 129.1, 128.5, 70.7, 67.2, 31.2, 29.9, 22.9, 






1-(3-tert-butylquinoxalin-2-yl)ethane-1,2-diol (S35): 1H NMR (600 MHz, CDCl3) δ 
ppm 8.06 (1H, d, J = 8.4 Hz), 7.99 (1H, d, J = 7.8 Hz), 7.71-7.76 (2H, m), 5.42-5.44 (1H, 
m), 3.97 (1H, dd, J = 11.6, 2.9 Hz), 3.83 (1H, dd, J = 11.6, 6.3 Hz), 1.59 (9H, s).  13C 
NMR (100 MHz, CDCl3) δ ppm 161.1, 154.7, 141.1, 139.3, 130.2, 129.8, 129.5, 128.2, 




1-(3-isobutylquinoxalin-2-yl) ethane-1,2-diol (S36):  1H NMR (400 MHz, CDCl3) δ 
8.05-8.11 (2H, m), 7.76-7.81 (2H, m), 5.21 (1H, t, J= 3.2, 3.2 Hz), 4.05 (1H, dd, J= 11.6, 
3.2 Hz), 3.79 (1H, dd, J= 11.6, 5.6 Hz), 2.95 (2H, d, J= 7.2 Hz), 2.44-2.47 (1H, m), 1.07 
(3H, d, J= 4.0 Hz), 1.06 (3H, d, J= 3.6 Hz); 13C NMR (100 MHz, CDCl3) δ 155.3, 153.2, 
142.4, 139.5, 130.4, 129.9, 129.2, 128.8, 71.0, 66.9, 43.2, 28.9, 23.2, 22.8. HRMS (m/z): 
Found, 247.1444 Calc’d. 247.1447 (M+H). 
 
  
1-(3-sec-butylquinoxalin-2-yl) ethane-1,2-diol (S37):  1H NMR (400 MHz, CDCl3) δ 




(1H, m), 3.18-3.22 (1H, m), 1.93-1.21 (1H, m), 1.75-1.85 (1H, m), 1.40 (3H, dd, J= 29.5, 
6.5 Hz), 0.90 (3H, dt, J= 20.5, 7.5, 7.5 Hz); 13C NMR (100 MHz, CDCl3) δ 130.2, 129.9, 
129.3, 128.7, 70.9, 67.3, 38.6, 38.3, 21.2, 20.2, 12.8, 12.6. HRMS (m/z): Found, 247.1446 
Calc’d. 247.1447 (M+H). 
 
 
1-(3-neopentylquinoxalin-2-yl) ethane-1,2-diol (S38):  1H NMR (400 MHz, CDCl3) δ 
8.05-8.13 (2H, m), 7.76-7.79 (2H, m), 5.29-5.33 (1H, m), 4.01 (1H, dd, J= 4.5, 3.2 Hz), 
3.73 (1H, dd, J= 6.0, 5.6 Hz), 3.02 (2H, q, J= 24.8,13.6, 13.6 Hz), 1.11 (9H, s); 13C NMR 
(100 MHz, CDCl3) δ 154.3, 153.7, 142.1, 130.4, 130.1, 129.4, 128.7, 71.4, 67.2, 46.2, 
34.1, 30.3. HRMS (m/z): Found, 261.1604 Calc’d. 261.1603 (M+H). 
 
 
1-(3-cyclopropylquinoxalin-2-yl)ethane-1,2-diol (S39): 1H NMR (500 MHz, CDCl3) δ 
ppm 8.01 (1H, dd, J = 8.0, 1.2 Hz), 7.96 (1H, dd, J = 8.3, 1.2 Hz), 7.65-7.72 (2H, m), 
5.36-5.39 (1H, m), 4.85 (1H, d, J = 6.0Hz), 4.17 (1H, d, J = 11.2Hz), 3.84 (1H, dd, J = 
6.0, 11.6Hz), 2.78 (1H, s, br), 2.27-2.32 (1H, m), 1.48-1.52 (1H, m), 1.23-1.27 (1H, m), 
1.15-1.21 (2H, m).  13C NMR (125 MHz, CDCl3) δ ppm 156.2, 152.3, 142.3, 138.9, 
129.9, 129.1, 128.8, 128.5, 71.1, 66.6, 13.8, 11.9, 10.6. HRMS (ESI+): Found 231.1133 






1-(3-cyclobutylquinoxalin-2-yl)ethane-1,2-diol (S40): 1H NMR (400 MHz, CDCl3) δ 
ppm 8.19-8.25 (2H, m), 7.80-7.90 (2H, m), 5.21-5.22 (1H, br), 4.04-4.11 (1H, m), 3.80-
3.83 (1H, m), 2.60-2.70 (2H, m), 2.33-2.47 (2H), 2.15-2.22 (2H, m), 1.93-2.07 (2H, m) 
13C NMR (100 MHz, CDCl3) δ ppm 131.1, 131.0, 129.4, 126.9, 71.1, 66.7, 38.5, 28.1, 




1-(3-cyclopentylquinoxalin-2-yl)ethane-1,2-diol (S41):  1H NMR (400 MHz, CDCl3) δ 
ppm 8.05-8.10 (2H, m), 7.73-7.77 (2H, m), 5.81 (1H, t, J= 3.2Hz), 4.07 (1H, dd, J= 3.2, 
11.6 Hz), 3.78 (1H, dd, J= 6.0, 11.6 Hz), 3.53-3.56 (1H, m), 2.15-2.17 (2H, m), 1.97-2.00 
(4H, m), 1.78-1.81 (2H, m); 13C NMR (100 MHz, CDCl3) δ ppm 159.5, 152.4, 142.7, 
139.3, 130.2, 129.8, 129.3, 128.5, 71.1, 67.4, 42.9, 34.7, 33.7, 26.6, 26.5 HRMS (ESI+): 
Found 259.2224 Calc’d  259.1368 (M+H). 
 
 
1-(3-cyclohexylquinoxalin-2-yl)ethane-1,2-diol (S42): 1H NMR (500 MHz, CDCl3) δ 




br), 4.66 (1H, s, br), 4.01-4.04 (1H, m), 3.75 (1H, dd, J = 11.5, 6.1 Hz), 3.01-3.07 (1H, 
m), 1.76-1.98 (6H, m), 1.44-1.49 (4H, m).  13C NMR (125 MHz, CDCl3) δ ppm 159.6, 
152.0, 142.5, 139.4, 130.0, 129.6, 129.1, 128.5, 70.7, 67.3, 41.7, 33.2, 32.0, 26.8, 26.1.  
HRMS (ESI+): Found 273.1618 Calc’d 273.1603 (M+H).  
 
  
1-(3-cycloheptylquinoxaline-2-yl) ethane-1,2-diol (S43): 1H NMR (400 MHz, CDCl3) δ 
ppm 8.03-8.12 (2H, m), 7.72-7.78 (2H, m), 5.20-5.27 (1H, m), 4.01-4.11 (1H, m), 3.73-
3.79 (1H, m), 3.19-3.28 (1H, m), 2.83-2.86 (1H, m), 2.14-2.22 (1H, m), 1.96-2.04 (4H, 
m), 1.75-1.83 (4H, m), 1.59-1.64 (4H, m) 13C NMR (100 MHz, CDCl3) δ 151.7, 130.2, 
129.7, 129.3, 128.7, 70.9, 67.3, 35.6, 34.3, 28.5, 28.3, 27.6, 27.5. MS (ESI+): Found 
287.27 Calc’d  287.17 (M+H).  
 
 
1-(3-(cyclohexylmethyl)quinoxalin-2-yl)ethane-1,2-diol (S44): 1H NMR (500 MHz, 
CDCl3) 8.03-8.12 (2H, m), 7.75-7.79 (2H, m), 5.18-5.21 (1H, m), 4.03 (1H, dd, J= 3.3, 
3.4 Hz), 3.73-3.79 (1H, m), 2.94 (2H, d, J= 7.0 Hz), 2.32-2.35 (1H, m), 1.12-1.17 (4H, 
m), 0.85-0.92 (6H, m) 13C NMR (100 MHz, CDCl3) δ 155.5, 153.6, 130.7, 130.3, 129.6, 







1-(3-phenyl-quinoxalin-2-yl)-ethane-1,2-diol (S45): 1H NMR (400 MHz, CDCl3) δ ppm 
8.08-8.16 (2H, m), 7.78-7.82 (2H, m), 7.75 (1H, dd, J= 0.8, 2.4 Hz), 7.44 (1H, dd, J= 0.8, 
2.8 Hz), 6.69-6.70 (1H, m), 5.74-5.76 (1H, m), 4.12 (1H, dd, J= 3.2, 11.6 Hz), 3.72 (1H, 
dd, J= 5.2, 11.6 Hz); 13C NMR (100 MHz, CDCl3) δ ppm 145.4, 131.0, 130.6, 129.5, 




1-(3-(furan-2-yl)quinoxalin-2-yl)ethane-1,2-diol (S46):  1H NMR (400 MHz, CDCl3) δ 
ppm 8.08-8.16 (2H, m), 7.78-7.82 (2H, m), 7.75 (1H, dd, J= 0.8, 2.4 Hz), 7.44 (1H, dd, 
J= 0.8, 2.8 Hz), 6.69-6.70 (1H, m), 5.74-5.76 (1H, m), 4.12 (1H, dd, J= 3.2, 11.6 Hz), 
3.72 (1H, dd, J= 5.2, 11.6 Hz); 13C NMR (100 MHz, CDCl3) δ ppm 145.4, 131.0, 130.6, 







1-(3-fluorophenyl-quinoxalin-2-yl)-ethane-1,2-diol (S47): 1H NMR (400 MHz, CDCl3) 
δ 8.51-8.59 (1H, m), 8.32-8.33 (1H, m), 7.98-8.00 (2H, m), 7.86-7.89 (2H, m), 7.74-7.78 
(2H, m), 5.43 (1H, t, J= 4, 3.6 Hz), 4.02 (1H, dd, J= 3.2, 9.2 Hz), 3.71 (1H, dd, J= 4.4, 12 
Hz) MS (m/z): Found 285.13 Calc’d. 285.15 (M+H). 
 
 
1-(3-(4-nitrophenyl)quinoxalin-2-yl)ethane-1,2-diol (S48): 1H NMR (400 MHz, 
CDCl3) δ 8.44-8.47 (2H, m), 8.17-8.22 (2H, m), 7.99-8.01 (2H, m), 7.89-7.92 (2H, m), 
5.19 (1H, t, J=  4.0, 4.4 Hz), 3.83 (1H, dd, J= 3.6, 8.0 Hz), 3.76 (1H, dd, J= 4.8, 6.8 Hz) 
MS (m/z): Found 312.12 Calc’d. 312.09 (M+H). 
 
 
1-(3-methylquinoxalin-2-yl) ethanol (S49): 1H NMR (400 MHz, CDCl3) δ 8.03-8.06 
(2H, m), 7.72-7.76 (2H, m), 5.19 (1H, q, J= 6.4 Hz), 2.77 (3H, s), 1.55 (3H, d, J= 6.4 
Hz). 13C NMR (100 MHz, CDCl3) δ 157.4, 151.5, 142.0, 139.9, 130.1, 129.8, 128.8, 
128.7, 67.0, 23.9, 22.3. HRMS (m/z): Found 189.1039  Calc’d. 189.1028 (M+H). 
 
 
1-(3-isobutylquinoxalin-2-yl) ethanol (S50): 1H NMR (500 MHz, CDCl3) δ 8.06-8.10 




7.2 Hz), 2.42-2.49 (1H, m), 1.56 (3H, d, J= 6.4 Hz), 1.08 (3H, d, J= 6.8 Hz), 1.00 (3H, d, 
J= 7.6 Hz); 13C NMR (125 MHz, CDCl3) δ 158.2, 155.2, 142.8, 140.4, 130.2, 130.0, 




1-(3-cyclohexylquinoxalin-2-yl) ethanol (S51): 1H NMR (400 MHz, CDCl3) δ 8.04-8.10 
(2H, m), 7.72-7.76 (2H, m), 5.29-5.31 (1H, m), 4.85 (1H, d, J= 7.6 Hz).  2.92-3.01 (1H, 
m), 1.86-2.02 (6H, m), 1.61-1.63 (1H, m), 1.56 (3H, d, J= 6.4 Hz), 1.44-1.57 (3H, m); 
13C NMR (100 MHz, CDCl3) δ 159.0, 156.4, 142.5, 139.7, 129.7, 129.6, 129.2, 128.7, 





5.5. Spectra of AI-2 analogs 

















































































































































































































































PC                 2.00
GB                    0
LB                 0.30 Hz
SSB                   0
WDW                  EM
SF          399.7300000 MHz
SI                32768
F2 ! Processing parameters
SFO1        399.7324685 MHz
PL1               !4.00 dB
P1                10.00 usec
NUC1                 1H
======== CHANNEL f1 ========
TD0                   1
D1           1.50000000 sec
TE                295.4 K
DE                 6.00 usec
DW               66.000 usec
RG                  128
AQ            2.5999219 sec
FIDRES         0.192317 Hz
SWH            7575.758 Hz
DS                    2
NS                   64
SOLVENT           CDCl3
TD                39392
PULPROG            zg30
PROBHD   5 mm QNP  1H/1
INSTRUM           spect
Time              14.57
Date_          20091021
F2 ! Acquisition Parameters
PROCNO                1
EXPNO                10



































































PC                 1.40
GB                    0
LB                 1.00 Hz
SSB                   0
WDW                  EM
SF          100.5121480 MHz
SI                32768
F2 ! Processing parameters
SFO2        399.7315989 MHz
PL12              17.37 dB
PL2               !4.00 dB
PCPD2             89.00 usec
NUC2                 1H
CPDPRG2         waltz16
======== CHANNEL f2 ========
SFO1        100.5242095 MHz
PL1                0.00 dB
P1                 4.50 usec
NUC1                13C
======== CHANNEL f1 ========
TD0                   1
d11          0.03000000 sec
D1           1.50000000 sec
TE                296.1 K
DE                 6.00 usec
DW               18.400 usec
RG                  362
AQ            1.2059124 sec
FIDRES         0.414641 Hz
SWH           27173.912 Hz
DS                   32
NS                 1300
SOLVENT           CDCl3
TD                65536
PULPROG          zgdc30
PROBHD   5 mm QNP  1H/1
INSTRUM           spect
Time              17.50
Date_          20091021
F2 ! Acquisition Parameters
PROCNO                1
EXPNO                20














































































































































































































































































































































































































PC                 2.00
GB                    0
LB                 0.30 Hz
SSB                   0
WDW                  EM
SF          399.7300000 MHz
SI                32768
F2 ! Processing parameters
SFO1        399.7324685 MHz
PL1               !4.00 dB
P1                10.00 usec
NUC1                 1H
======== CHANNEL f1 ========
TD0                   1
D1           1.50000000 sec
TE                294.9 K
DE                 6.00 usec
DW               66.000 usec
RG                  256
AQ            2.5999219 sec
FIDRES         0.192317 Hz
SWH            7575.758 Hz
DS                    2
NS                   64
SOLVENT           CDCl3
TD                39392
PULPROG            zg30
PROBHD   5 mm QNP  1H/1
INSTRUM           spect
Time              13.00
Date_          20090817
F2 ! Acquisition Parameters
PROCNO                1
EXPNO                10
























































































































PC                 1.40
GB                    0
LB                 1.00 Hz
SSB                   0
WDW                  EM
SF          100.5121480 MHz
SI                32768
SFO2        399.7315989 MHz
PL12              17.37 dB
PL2               !4.00 dB
PCPD2             89.00 usec
NUC2                 1H
CPDPRG2         waltz16
======== CHANNEL f2 ========
SFO1        100.5242095 MHz
PL1                0.00 dB
P1                 4.50 usec
NUC1                13C
======== CHANNEL f1 ========
TD0                   1
d11          0.03000000 sec
D1           1.50000000 sec
TE                295.6 K
DE                 6.00 usec
DW               18.400 usec
RG                  181
AQ            1.2059124 sec
FIDRES         0.414641 Hz
SWH           27173.912 Hz
DS                   16
NS                 3800
SOLVENT           CDCl3
TD                65536
PULPROG          zgdc30
PROBHD   5 mm QNP  1H/1
INSTRUM           spect
Time              23.08
Date_          20090817
PROCNO                1
EXPNO                11




















































































Cyclohexyl-DPD (1-cyclohexyl-3,4-dihydroxybutane-1,2-dione) and cyclic 











































































































































































































PC                 2.00
GB                    0
LB                 0.30 Hz
SSB                   0
WDW                  EM
SF          399.7300000 MHz
SI                32768
F2 ! Processing parameters
SFO1        399.7324685 MHz
PL1               !4.00 dB
P1                10.00 usec
NUC1                 1H
======== CHANNEL f1 ========
TD0                   1
D1           1.50000000 sec
TE                295.0 K
DE                 6.00 usec
DW               66.000 usec
RG                  128
AQ            2.5999219 sec
FIDRES         0.192317 Hz
SWH            7575.758 Hz
DS                    2
NS                   64
SOLVENT             D2O
TD                39392
PULPROG            zg30
PROBHD   5 mm QNP  1H/1
INSTRUM           spect
Time               9.12
Date_          20091012
F2 ! Acquisition Parameters
PROCNO                1
EXPNO                11
































































































































































































































































































































PC                 1.00
GB                    0
LB                 0.30 Hz
SSB                   0
WDW                  EM
SF          500.1300082 MHz
SI                32768
F2 ! Processing parameters
SFO1        500.1330008 MHz
PL1                0.00 dB
P1                11.10 usec
NUC1                 1H
======== CHANNEL f1 ========
TD0                   1
D1           4.00000000 sec
TE                296.6 K
DE                 9.00 usec
DW               76.800 usec
RG                  181
AQ            5.0332146 sec
FIDRES         0.099341 Hz
SWH            6510.417 Hz
DS                    2
NS                   16
SOLVENT           CDCl3
TD                65536
PULPROG              zg
PROBHD   5 mm BBO2 new
INSTRUM           spect
Time              11.45
Date_          20090810
F2 ! Acquisition Parameters
PROCNO                1
EXPNO                 1
























































































PC                 2.00
GB                    0
LB                 0.30 Hz
SSB                   0
WDW                  EM
SF          399.7300000 MHz
SI                32768
F2 ! Processing parameters
SFO1        399.7324685 MHz
PL1               !4.00 dB
P1                10.00 usec
NUC1                 1H
======== CHANNEL f1 ========
TD0                   1
D1           1.50000000 sec
TE                295.0 K
DE                 6.00 usec
DW               66.000 usec
RG                  128
AQ            2.5999219 sec
FIDRES         0.192317 Hz
SWH            7575.758 Hz
DS                    2
NS                   64
SOLVENT           CDCl3
TD                39392
PULPROG            zg30
PROBHD   5 mm QNP  1H/1
INSTRUM           spect
Time              10.34
Date_          20091214
F2 ! Acquisition Parameters
PROCNO                1
EXPNO                10





























PC                 2.00
GB                    0
LB                 0.30 Hz
SSB                   0
WDW                  EM
SF          399.7300000 MHz
SI                32768
F2 ! Processing parameters
SFO1        399.7324685 MHz
PL1               !4.00 dB
P1                10.00 usec
NUC1                 1H
======== CHANNEL f1 ========
TD0                   1
D1           1.50000000 sec
TE                295.2 K
DE                 6.00 usec
DW               66.000 usec
RG                456.1
AQ            2.5999219 sec
FIDRES         0.192317 Hz
SWH            7575.758 Hz
DS                    2
NS                   64
SOLVENT           CDCl3
TD                39392
PULPROG            zg30
PROBHD   5 mm QNP  1H/1
INSTRUM           spect
Time              19.28
Date_          20091110
F2 ! Acquisition Parameters
PROCNO                1
EXPNO                10






























































































































































































































































































































PC                 2.00
GB                    0
LB                 0.30 Hz
SSB                   0
WDW                  EM
SF          399.7300000 MHz
SI                32768
F2 ! Processing parameters
SFO1        399.7324685 MHz
PL1               !4.00 dB
P1                10.00 usec
NUC1                 1H
======== CHANNEL f1 ========
TD0                   1
D1           1.50000000 sec
TE                294.9 K
DE                 6.00 usec
DW               66.000 usec
RG                574.7
AQ            2.5999219 sec
FIDRES         0.192317 Hz
SWH            7575.758 Hz
DS                    2
NS                   64
SOLVENT           CDCl3
TD                39392
PULPROG            zg30
PROBHD   5 mm QNP  1H/1
INSTRUM           spect
Time              16.41
Date_          20090916
F2 ! Acquisition Parameters
PROCNO                1
EXPNO                10



































































































PC                 1.40
GB                    0
LB                 1.00 Hz
SSB                   0
WDW                  EM
SF          100.5121480 MHz
SI                32768
F2 ! Processing parameters
SFO2        399.7315989 MHz
PL12              17.37 dB
PL2               !4.00 dB
PCPD2             89.00 usec
NUC2                 1H
CPDPRG2         waltz16
======== CHANNEL f2 ========
SFO1        100.5242095 MHz
PL1                0.00 dB
P1                 4.50 usec
NUC1                13C
======== CHANNEL f1 ========
TD0                   1
d11          0.03000000 sec
D1           1.50000000 sec
TE                295.7 K
DE                 6.00 usec
DW               18.400 usec
RG                287.4
AQ            1.2059124 sec
FIDRES         0.414641 Hz
SWH           27173.912 Hz
DS                   16
NS                 3800
SOLVENT           CDCl3
TD                65536
PULPROG          zgdc30
PROBHD   5 mm QNP  1H/1
INSTRUM           spect
Time              20.05
Date_          20090917
F2 ! Acquisition Parameters
PROCNO                1
EXPNO                10











































































































































































































































































































PC                 2.00
GB                    0
LB                 0.30 Hz
SSB                   0
WDW                  EM
SF          399.7300000 MHz
SI                32768
F2 ! Processing parameters
SFO1        399.7324685 MHz
PL1               !4.00 dB
P1                10.00 usec
NUC1                 1H
======== CHANNEL f1 ========
TD0                   1
D1           1.50000000 sec
TE                295.0 K
DE                 6.00 usec
DW               66.000 usec
RG                   64
AQ            2.5999219 sec
FIDRES         0.192317 Hz
SWH            7575.758 Hz
DS                    2
NS                   64
SOLVENT           CDCl3
TD                39392
PULPROG            zg30
PROBHD   5 mm QNP  1H/1
INSTRUM           spect
Time              10.21
Date_          20091214
F2 ! Acquisition Parameters
PROCNO                1
EXPNO                10































































































































































































































































PC                 2.00
GB                    0
LB                 0.30 Hz
SSB                   0
WDW                  EM
SF          399.7300000 MHz
SI                32768
F2 ! Processing parameters
SFO1        399.7324685 MHz
PL1               !4.00 dB
P1                10.00 usec
NUC1                 1H
======== CHANNEL f1 ========
TD0                   1
D1           1.50000000 sec
TE                295.0 K
DE                 6.00 usec
DW               66.000 usec
RG                  128
AQ            2.5999219 sec
FIDRES         0.192317 Hz
SWH            7575.758 Hz
DS                    2
NS                   64
SOLVENT           CDCl3
TD                39392
PULPROG            zg30
PROBHD   5 mm QNP  1H/1
INSTRUM           spect
Time              10.02
Date_          20091214
F2 ! Acquisition Parameters
PROCNO                1
EXPNO                10
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